<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">

<pmc-articleset><article article-type="research-article" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">
<?properties open_access?>
<front>
<journal-meta>
<journal-id journal-id-type="nlm-ta">eNeuro</journal-id>
<journal-id journal-id-type="iso-abbrev">eNeuro</journal-id>
<journal-id journal-id-type="hwp">eneuro</journal-id>
<journal-id journal-id-type="pmc">eneuro</journal-id>
<journal-id journal-id-type="publisher-id">eNeuro</journal-id>
<journal-title-group>
<journal-title>eNeuro</journal-title>
</journal-title-group>
<issn pub-type="epub">2373-2822</issn>
<publisher>
<publisher-name>Society for Neuroscience</publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="pmid">31147392</article-id>
<article-id pub-id-type="pmc">6565377</article-id>
<article-id pub-id-type="doi">10.1523/ENEURO.0097-19.2019</article-id>
<article-id pub-id-type="publisher-id">eN-NWR-0097-19</article-id>
<article-categories>
<subj-group subj-group-type="hwp-journal-coll">
<subject>3</subject>
<subject>3.1</subject>
</subj-group>
<subj-group subj-group-type="heading">
<subject>New Research</subject>
<subj-group>
<subject>Disorders of the Nervous System</subject>
</subj-group>
</subj-group>
</article-categories>
<title-group>
<article-title>Lovastatin, not Simvastatin, Corrects Core Phenotypes in the Fragile X Mouse Model</article-title>
<alt-title alt-title-type="right-running-head">Lovastatin, not Simvastatin, Is Corrective for Fragile X</alt-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname>Muscas</surname>
<given-names>Melania</given-names>
</name>
<xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Louros</surname>
<given-names>Susana R.</given-names>
</name>
<xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref>
</contrib>
<contrib contrib-type="author" corresp="yes">
<contrib-id authenticated="false" contrib-id-type="orcid">http://orcid.org/0000-0003-0582-2284</contrib-id>
<name>
<surname>Osterweil</surname>
<given-names>Emily K.</given-names>
</name>
<xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref>
</contrib>
<aff id="aff1"><label>1</label>Centre for Discovery Brain Sciences, Simons Initiative for the Developing Brain, <institution>University of Edinburgh</institution>, Edinburgh EH8 9XD, <country>United Kingdom</country></aff>
</contrib-group>
<author-notes>
<fn fn-type="other">
<p>The authors declare no competing financial interests.</p>
</fn>
<fn fn-type="con">
<p>Author contributions: M.M., S.R.L., and E.K.O. designed research; M.M. and S.R.L. performed research; M.M. and S.R.L. analyzed data; M.M., S.R.L., and E.K.O. wrote the paper.</p>
</fn>
<fn fn-type="supported-by">
<p>This work was supported by the Wellcome Trust/Royal Society Sir Henry Dale Fellowship 104116/Z/14/Z, the Medical Research Council Grant MR/M006336/1, and Simons Initiative for the Developing Brain.</p>
</fn>
<corresp id="cor1">Correspondence should be addressed to Emily K. Osterweil at <email>emily.osterweil@ed.ac.uk</email></corresp>
</author-notes>
<pub-date pub-type="epreprint">
<day>30</day>
<month>5</month>
<year>2019</year>
</pub-date>
<pub-date pub-type="epub">
<day>10</day>
<month>6</month>
<year>2019</year>
</pub-date>
<pub-date pub-type="collection">
<season>May-Jun</season>
<year>2019</year>
</pub-date>
<volume>6</volume>
<issue>3</issue>
<elocation-id>ENEURO.0097-19.2019</elocation-id>
<history>
<date date-type="received">
<day>15</day>
<month>3</month>
<year>2019</year>
</date>
<date date-type="rev-recd">
<day>11</day>
<month>5</month>
<year>2019</year>
</date>
<date date-type="accepted">
<day>13</day>
<month>5</month>
<year>2019</year>
</date>
</history>
<permissions>
<copyright-statement>Copyright © 2019 Muscas et al.</copyright-statement>
<copyright-year>2019</copyright-year>
<copyright-holder>Muscas et al.</copyright-holder>
<license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by/4.0/">
<license-p>This is an open-access article distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution 4.0 International license</ext-link>, which permits unrestricted use, distribution and reproduction in any medium provided that the original work is properly attributed.</license-p>
</license>
</permissions>
<self-uri content-type="pdf" xlink:href="ENEURO.0097-19.2019.pdf"></self-uri>
<self-uri xlink:href="enu00319295500g1.jpg" xlink:role="icon"></self-uri>
<abstract abstract-type="graphical">
<title>Visual Abstract</title>
<p><fig fig-type="featured" id="F4" orientation="portrait" position="float"><graphic xlink:href="enu003192955r001"></graphic></fig>
</p>
</abstract>
<abstract>
<p>The cholesterol-lowering drug lovastatin corrects neurological phenotypes in animal models of fragile X syndrome (FX), a commonly identified genetic cause of autism and intellectual disability (ID). The therapeutic efficacy of lovastatin is being tested in clinical trials for FX; however, the structurally similar drug simvastatin has been proposed as an alternative due to an increased potency and brain penetrance. Here, we perform a side-by-side comparison of the effects of lovastatin and simvastatin treatment on two core phenotypes in <italic>Fmr1<sup>-/y</sup></italic> mice versus WT littermates: excessive hippocampal protein synthesis and susceptibility to audiogenic seizures (AGSs). We find that simvastatin does not correct excessive hippocampal protein synthesis in the <italic>Fmr1<sup>-/y</sup></italic> hippocampus at any dose tested. In fact, simvastatin significantly increases protein synthesis in both <italic>Fmr1<sup>-/y</sup></italic> and WT. Moreover, injection of simvastatin does not reduce AGS in the <italic>Fmr1<sup>-/y</sup></italic> mouse, while lovastatin significantly reduces AGS incidence and severity versus vehicle-treated animals. These results show that unlike lovastatin, simvastatin does not correct core phenotypes in the <italic>Fmr1<sup>-/y</sup></italic> mouse model.</p>
</abstract>
<kwd-group>
<kwd>ERK</kwd>
<kwd>FMR1</kwd>
<kwd>fragile X</kwd>
<kwd>lovastatin</kwd>
</kwd-group>
<funding-group>
<award-group>
<funding-source><named-content content-type="funder-id">http://doi.org/10.13039/100010269</named-content>Wellcome Trust (Wellcome)</funding-source>
<award-id>Sir Henry Dale fellowship 104116/Z/14/Z</award-id>
</award-group>
<award-group>
<funding-source><named-content content-type="funder-id">http://doi.org/10.13039/501100000265</named-content>Medical Research Council (MRC)</funding-source>
<award-id>MR/M006336/1</award-id>
</award-group>
<award-group>
<funding-source>Simons Initiative for the Developing Brain</funding-source>
</award-group>
</funding-group>
<counts>
<fig-count count="4"></fig-count>
<table-count count="1"></table-count>
<equation-count count="0"></equation-count>
<ref-count count="53"></ref-count>
<page-count count="12"></page-count>
<word-count count="8961"></word-count>
</counts>
<custom-meta-group>
<custom-meta>
<meta-name>cover-date</meta-name>
<meta-value>May/June 2019</meta-value>
</custom-meta>
</custom-meta-group>
</article-meta>
</front>
<body>
<sec id="s1" sec-type="intro">
<title>Significance Statement</title>
<p>The statin drug lovastatin is in clinical trials for the treatment of fragile X syndrome (FX), and the structurally similar drug simvastatin has been proposed as a viable alternative. This study compares the efficacy of these drugs for ameliorating two major phenotypes in the FX mouse model and shows that although lovastatin is effective in correcting excessive protein synthesis and audiogenic seizures (AGSs), simvastatin fails to correct either phenotype. These results suggest caution should be used when assuming simvastatin is a suitable substitute for lovastatin with respect to the treatment of FX or other neurodevelopmental disorders.</p>
</sec>
<sec id="s2" sec-type="intro">
<title>Introduction</title>
<p>Fragile X syndrome (FX) is a monogenic neurodevelopmental disorder characterized by severe intellectual disability (ID), autism, hypersensitivity to sensory stimulation and epilepsy (<xref ref-type="bibr" rid="B25">Lozano et al., 2014</xref>). FX occurs in 1:4000 males and 1:8000 females, making it one of the most commonly identified genetic causes of autism and ID (<xref ref-type="bibr" rid="B11">Hagerman et al., 2009</xref>; <xref ref-type="bibr" rid="B25">Lozano et al., 2014</xref>). The <italic>FMR1</italic> gene mutated in FX encodes fragile X mental retardation protein (FMRP), which represses mRNA translation in neurons (<xref ref-type="bibr" rid="B2">Ashley et al., 1993</xref>; <xref ref-type="bibr" rid="B9">Darnell et al., 2011</xref>). Studies of the <italic>Fmr1<sup>-/y</sup></italic> mouse model of FX reveal that excessive cerebral protein synthesis is a major consequence of <italic>Fmr1</italic> deletion (<xref ref-type="bibr" rid="B38">Qin et al., 2005</xref>; <xref ref-type="bibr" rid="B10">Dölen et al., 2007</xref>; <xref ref-type="bibr" rid="B6">Berry-Kravis et al., 2017</xref>; <xref ref-type="bibr" rid="B45">Stoppel et al., 2017b</xref>), which can be normalized through antagonism of metabotropic glutamate receptor 5 (mGlu<sub>5</sub>) or the downstream extracellular regulated kinase 1/2 (ERK1/2) MAP kinase and mammalian target of rapamycin (mTOR)-p70 S6 kinase (p70S6K) signaling pathways (<xref ref-type="bibr" rid="B10">Dölen et al., 2007</xref>; <xref ref-type="bibr" rid="B33">Osterweil et al., 2010</xref>; <xref ref-type="bibr" rid="B43">Sharma et al., 2010</xref>; <xref ref-type="bibr" rid="B28">Michalon et al., 2012</xref>; <xref ref-type="bibr" rid="B49">Wang et al., 2012</xref>). These strategies correct multiple neurologic phenotypes in the <italic>Fmr1<sup>-/y</sup></italic> mouse, including an enhanced susceptibility to audiogenic seizures (AGSs; <xref ref-type="bibr" rid="B3">Bear et al., 2004</xref>; <xref ref-type="bibr" rid="B10">Dölen et al., 2007</xref>; <xref ref-type="bibr" rid="B33">Osterweil et al., 2010</xref>; <xref ref-type="bibr" rid="B44">Stoppel et al., 2017a</xref>). The current challenge is to successfully transition these therapeutic approaches to the clinic.</p>
<p>Previous work shows that the statin drug lovastatin, currently used for the treatment of high cholesterol in adults and children, resolves neuropathology in the <italic>Fmr1<sup>-/y</sup></italic> mouse model (<xref ref-type="bibr" rid="B34">Osterweil et al., 2013</xref>). Lovastatin normalizes protein synthesis by reducing the farnesylation and subsequent activation of the GTPase Ras, which lies upstream of the ERK1/2 signaling pathway (<xref ref-type="bibr" rid="B42">Schafer et al., 1989</xref>; <xref ref-type="bibr" rid="B27">Mendola and Backer, 1990</xref>). By this mechanism, lovastatin has also been shown to successfully correct electrophysiological and behavioral phenotypes in the mouse model of neurofibromatosis type 1 (NF1), a neurodevelopmental disorder of excess Ras (<xref ref-type="bibr" rid="B21">Li et al., 2005</xref>). In contrast to ERK1/2, the mTOR-p70S6K pathway activated by the GTPase Rheb is not altered by lovastatin suggesting the impact on farnesylation does not extend to all targets (<xref ref-type="bibr" rid="B34">Osterweil et al., 2013</xref>).</p>
<p>In the <italic>Fmr1<sup>-/y</sup></italic> mouse, the reduction of Ras-ERK1/2 by lovastatin ameliorates hippocampal epileptogenesis and neocortical hyperexcitability and significantly reduces the incidence of AGS (<xref ref-type="bibr" rid="B34">Osterweil et al., 2013</xref>). The AGS phenotype is one of the most robust behavioral phenotypes seen in the <italic>Fmr1<sup>-/y</sup></italic> mouse, and it models the epilepsy observed in FX patients (<xref ref-type="bibr" rid="B29">Musumeci et al., 2000</xref>; <xref ref-type="bibr" rid="B5">Berry-Kravis, 2002</xref>). Several previous studies have used AGS as a benchmark for determining the efficacy of potential treatment strategies, consistently finding a positive correlation between treatment efficacy at reducing seizure incidence and correction of other pathologies (<xref ref-type="bibr" rid="B53">Yan et al., 2005</xref>; <xref ref-type="bibr" rid="B10">Dölen et al., 2007</xref>; <xref ref-type="bibr" rid="B33">Osterweil et al., 2010</xref>, <xref ref-type="bibr" rid="B34">2013</xref>; <xref ref-type="bibr" rid="B7">Busquets-Garcia et al., 2013</xref>; <xref ref-type="bibr" rid="B17">King and Jope, 2013</xref>). Based on the positive outcome with lovastatin in <italic>Fmr1<sup>-/y</sup></italic> animal models, two open-label clinical trials tested the viability of lovastatin for the treatment of FX (<xref ref-type="bibr" rid="B8">Çaku et al., 2014</xref>; <xref ref-type="bibr" rid="B36">Pellerin et al., 2016</xref>). Both studies revealed a significant improvement with lovastatin treatment, and a double-blind placebo-controlled trial is ongoing (<xref ref-type="bibr" rid="B6">Berry-Kravis et al., 2017</xref>).</p>
<p>Interestingly, the availability of lovastatin is not widespread in Europe and is not licensed for use in the United Kingdom. Instead, the drug simvastatin has been proposed as an alternative therapeutic. Simvastatin is a structurally similar derivative of lovastatin that is twice as potent, with a daily dose of only 10 mg reducing cholesterol by 25–30% compared to 20 mg of lovastatin (<xref ref-type="bibr" rid="B16">Jones et al., 1998</xref>; <xref ref-type="bibr" rid="B41">Schaefer et al., 2004</xref>; <xref ref-type="bibr" rid="B31">Neuvonen et al., 2008</xref>). Simvastatin is also more brain penetrant than lovastatin, suggesting it may be a better option for neurologic indications (<xref ref-type="bibr" rid="B46">Tsuji et al., 1993</xref>). However, simvastatin has not been investigated in the <italic>Fmr1<sup>-/y</sup></italic> model, and the impact on Ras-ERK1/2 signaling in the brain is not well established. This information is critical, as clinical trials in NF1 have recently shown that lovastatin has a beneficial impact on cognitive function whereas simvastatin does not (<xref ref-type="bibr" rid="B19">Krab et al., 2008</xref>; <xref ref-type="bibr" rid="B1">Alabama-Birmingham and NCI, 2009, 2010</xref>; <xref ref-type="bibr" rid="B47">van der Vaart et al., 2013</xref>; <xref ref-type="bibr" rid="B4">Bearden et al., 2016</xref>; <xref ref-type="bibr" rid="B35">Payne et al., 2016</xref>).</p>
<p>In this study, we performed a side-by-side comparison of lovastatin and simvastatin to answer the simple but important question of whether there is a similar rescue of pathology in the <italic>Fmr1<sup>-/y</sup></italic> mouse. We focused on two core phenotypes in the <italic>Fmr1<sup>-/y</sup></italic> model: excessive protein synthesis and enhanced susceptibility to AGS. Importantly, our results clearly show that lovastatin, but not simvastatin, is effective in reducing ERK1/2 activity and normalizing protein synthesis in the <italic>Fmr1<sup>-/y</sup></italic> hippocampus. This suggests that simvastatin acts via a different mechanism from lovastatin with respect to ERK1/2-driven protein synthesis in the brain. To examine whether there was a similar impact on pathology, we performed a thorough AGS analysis using multiple doses of simvastatin. The results of these experiments show that simvastatin does not reduce the incidence or severity of AGS in the <italic>Fmr1<sup>-/y</sup></italic> mouse under conditions where lovastatin is significantly effective. Together, this evidence suggests simvastatin may not be a suitable replacement for lovastatin with respect to the treatment of FX.</p>
</sec>
<sec id="s3" sec-type="materials|methods">
<title>Materials and Methods</title>
<sec id="s3A">
<title>Mice</title>
<p>All mice tested were male and were naive to drug and behavioral testing before experimentation. Mice were group housed with unrestricted food and water access and a 12/12 h light/dark cycle. Room temperature was maintained at 21 ± 2°C. All animal procedures were performed in accordance with the University of Edinburgh animal care committee’s regulations and the United Kingdom Animals Act. <italic>Fmr1<sup>-/y</sup></italic> mice (The Jackson Laboratory 003025, RRID:<ext-link ext-link-type="uri" xlink:href="https://scicrunch.org/resolver/IMSR_JAX:003025">IMSR_JAX:003025</ext-link>) were maintained on either a C57BL/6J (Charles River) or a mixed C57BL/6J x FVB background (C57BL/6J backcrossed to FVB by two generations).</p>
</sec>
<sec id="s3B">
<title>Metabolic labeling</title>
<p>Hippocampal slices were prepared from male littermate wild-type (WT) and <italic>Fmr1<sup>-/y</sup></italic> (KO) C57BL/6J mice [postnatal day (P)25–P32], in an interleaved fashion, with the experimenter blind to genotype. Mice were anaesthetized with isoflurane, and the hippocampus was rapidly dissected in ice-cold ACSF (124 mM NaCl, 3 mM KCl, 1.25 mM NaH<sub>2</sub>PO<sub>4</sub>, 26 mM NaHCO<sub>3</sub>, 10 mM dextrose, 1 mM MgCl<sub>2</sub>, and 2 mM CaCl<sub>2</sub>, saturated with 95% O<sub>2</sub> and 5% CO<sub>2</sub>). Slices (500 µm thick) were prepared using a Stoelting Tissue Slicer and transferred into 32.5°C ACSF (saturated with 95% O<sub>2</sub> and 5% CO<sub>2</sub>) within 5 min. Slices were incubated in 32.5°C ACSF for 4 h to allow for recovery of protein synthesis then transferred to ACSF containing 25 μM Actinomycin D (Tocris) plus either vehicle (0.05% DMSO in ddH<sub>2</sub>O), 50 μM lovastatin active form (CAS 75225-50-2; Calbiochem Merck Millipore), or 0.1–5 μM simvastatin active form (CAS 101314-97-0; Cayman Chemical) for 30 min. To measure new protein synthesis, slices were then transferred to fresh ACSF with 10 µCi/ml <sup>35</sup>S-Met/Cys (PerkinElmer) containing vehicle (veh) or drug for another 30 min.</p>
<p>After labeling, slices were homogenized in ice-cold buffer (10 mM HEPES, pH 7.4, 2 mM EDTA, 2 mM EGTA, 1% Triton X-100, protease inhibitors, and phosphatase inhibitors) and incubated in trichloroacetic acid (TCA; 10% final) for 10 min on ice before being centrifuged at 16,000 rpm for 10 min. The pellet was washed in ice-cold ddH<sub>2</sub>O and resuspended in 1 N NaOH until dissolved, and the pH was readjusted to neutral using 0.33 N HCl. Triplicates of each sample were subjected to scintillation counting and protein concentration assay kit (Bio-Rad). Counts per minute (CPM) were divided by protein concentration, and this was normalized to the CPM from the ACSF used for incubation. For display purposes, example slice homogenates were resolved on SDS-PAGE gels, transferred to nitrocellulose and exposed to a phosphorimaging screen (GE Healthcare). Phosphorimages were acquired using a Typhoon scanner (GE Healthcare) and compared to total protein staining of the same membrane.</p>
</sec>
<sec id="s3C">
<title>Immunoblotting</title>
<p>Samples were loaded on SDS-PAGE gels, with all conditions per littermate pair (i.e., WT veh, KO veh, WT drug, KO drug) present on the same gel (Extended Data <xref ref-type="supplementary-material" rid="fig2-1">Fig. 2-1</xref>). Samples were coded such that the experimenter was blinded to genotype and treatment. Gels were transferred to nitrocellulose and stained for total protein with the Memcode Reversible staining kit (Pierce). To immunoblot for ERK1/2 and p70S6K in the same samples, membranes were cut at 75, 50, and 37 kDa as shown in Extended Data <xref ref-type="supplementary-material" rid="fig2-1">Figure 2-1</xref>. For membranes probed for p-p70S6K, the portion of membrane above 75 kDa was removed to eliminate the background p85S6K band recognized by this antibody. Each membrane was then blo<italic>c</italic>ked with 5% BSA in TBS + 0.1% Tween 20 and incubated in primary antibody overnight at 4°C [Cell Signaling Technology; phospho-ERK1/2 (Thr202/Tyr204) 1:2000 (#9106, RRID:<ext-link ext-link-type="uri" xlink:href="https://scicrunch.org/resolver/AB_331768">AB_331768</ext-link>), ERK1/2 1:2000 (#9102, RRID:<ext-link ext-link-type="uri" xlink:href="https://scicrunch.org/resolver/AB_330744">AB_330744</ext-link>), phospho-p70S6K (Thr389) 1:1000 (#9234, RRID:<ext-link ext-link-type="uri" xlink:href="https://scicrunch.org/resolver/AB_2269803">AB_2269803</ext-link>), p70S6K 1:1000 (#2708, RRID:<ext-link ext-link-type="uri" xlink:href="https://scicrunch.org/resolver/AB_390722">AB_390722</ext-link>); Extended Data <xref ref-type="supplementary-material" rid="fig2-1">Fig. 2-1</xref>]. Membranes were then washed, incubated with HRP-conjugated secondary antibodies for 30 min (Cell Signaling; RRID:<ext-link ext-link-type="uri" xlink:href="https://scicrunch.org/resolver/AB_330924">AB_330924</ext-link> and RRID:<ext-link ext-link-type="uri" xlink:href="https://scicrunch.org/resolver/AB_2099233">AB_2099233</ext-link>), and developed with Clarity ECL (Bio-Rad). Densitometry was performed on scanned blot films using Image Studio Lite software, RRID: <ext-link ext-link-type="uri" xlink:href="https://scicrunch.org/resolver/SCR_013715">SCR_013715</ext-link>.</p>
<supplementary-material content-type="local-data" id="fig2-1">
<object-id pub-id-type="doi">10.1523/ENEURO.0097-19.2019.f2-1</object-id>
<label>Extended Data Figure 2-1</label>
<caption>
<p><bold><italic>A</italic></bold>, Original immunoblots used for representative images in <xref ref-type="fig" rid="F2">Figure 2</xref>. <bold><italic>B</italic></bold>, Memcode-stained membranes were cut at 75 , 50, and 37 kDa to allow for analysis of ERK1/2 and p70S6K activation in the same samples. This strategy also removed p85S6K to prevent background binding of the p-p70S6K antibody. <bold><italic>C</italic></bold>, Membranes used for analysis of p70S6K and ERK1/2 activation are shown. <italic>Figure Contributions</italic>: Melania Muscas and Susana R. Louros performed the experiments and analyzed the data. Download <inline-supplementary-material content-type="local-data" id="f2-1" mime-subtype="tiff" mimetype="image" xlink:href="sup_enu-eN-NWR-0097-19-s03.tif">Figure 2-1, TIF file</inline-supplementary-material>.</p>
</caption>
</supplementary-material>
<p>To compare phopho to total for each target in the same lane, membranes developed for phospho [i.e., phosphorylated (p-)ERK1/2] were stripped and reprobed for total (i.e., ERK1/2). Phosphorylation of target proteins was calculated as a ratio of phospho to total. To correct for blot-to-blot variance, each signal was normalized to the average signal of all lanes on the same blot. Values are shown as a percentage of average WT vehicle for graphical purposes. All membranes were analyzed with experimenter blind to genotype and treatment.</p>
</sec>
<sec id="s3D">
<title>AGSs</title>
<p>Test cohorts were counterbalanced for genotype and treatment. Naive WT and <italic>Fmr1<sup>-/y</sup></italic> male P18–P29 mice bred on a mixed C57BL/6J x FVB background were weighed and injected intraperitoneally with 3 mg/kg simvastatin prodrug (CAS 79902-63-9), 50 mg/kg simvastatin active form (CAS 101314-97-0), or 100 mg/kg lovastatin active form (CAS 75225-50-2) or respective vehicle (3%, 20%, or 50% DMSO + 10% Tween 80 in PBS). Animals were then transferred to a quiet (&lt;60-dB ambient sound) room for 1 h. For testing, animals were moved to a transparent test chamber equipped with speakers and a webcam and allowed to habituate for 1 min. Audiogenic stimulation (recorded sampling of a modified personal alarm) was passed through an amplifier and 2 × 50-W speakers (KRK Rokit RP5 G3 Active Studio Monitor) to produce a stimulus of &gt;130 dB for 2 min. A decibel meter was placed at a standard distance from the speakers to ensure a stable emission of sound throughout each session. Incidence and severity of seizures was scored and video files for each session were saved. Latency was measured as the number of seconds between onset of the AGS stimulus and appearance of the first seizure. Stages of AGS severity were assigned according to previous work as follows: (1) wild running (WR; pronounced, undirected running and thrashing), (2) clonic seizure (violent spasms accompanied by loss of balance), or (3) tonic seizure (loss of movement and postural rigidity in limbs and tail). Any animal that reached tonic seizure was immediately humanely killed. All injections, testing and scoring was performed with the experimenter blind to genotype and treatment.</p>
</sec>
<sec id="s3E">
<title>Statistics</title>
<p>Statistical testing was performed using GraphPad Prism 6 software, RRID: <ext-link ext-link-type="uri" xlink:href="https://scicrunch.org/resolver/SCR_002798">SCR_002798</ext-link>. For biochemistry experiments, outliers &gt;2 SD from the mean were removed and significance determined by repeated measures two-way ANOVA and <italic>post hoc</italic> Sidak’s multiple comparisons test. Significance for AGS incidence was determined using Fisher’s exact test. AGS severity score distributions were tested for normality and found to be non-normal by Shapiro–Wilk test. These score distributions were then statistically compared using a Mann–Whitney <italic>U</italic> test for analysis of ordinal datasets with non-normal distributions. Significant differences in latency to first seizure were determined using unpaired two-tailed Student’s <italic>t</italic> test. Results of all statistical analyses are reported in detail in the statistical table (<xref ref-type="table" rid="T1">Table 1</xref>) and figure legends.</p>
<table-wrap id="T1" orientation="portrait" position="float">
<label>Table 1.</label>
<caption>
<p>Statistics table
</p>
</caption>
<table frame="hsides" rules="none">
<colgroup span="1">
<col align="left" span="1" valign="top"/>
<col align="left" span="1" valign="top"/>
<col align="left" span="1" valign="top"/>
<col align="left" span="1" valign="top"/>
<col align="left" span="1" valign="top"/>
</colgroup>
<thead>
<tr>
<th align="center" colspan="1" rowspan="1">Figure</th>
<th align="center" colspan="1" rowspan="1">Data structure</th>
<th align="center" colspan="1" rowspan="1">Statistical test</th>
<th align="center" colspan="1" rowspan="1">Sample size</th>
<th align="center" colspan="1" rowspan="1">Statistical data</th>
</tr>
</thead>
<tbody valign="top">
<tr>
<td align="center" colspan="5" rowspan="1"><xref ref-type="fig" rid="F1">Figure 1<italic>B</italic></xref>, metabolic labelling of protein synthesis with 50 μM lovastatin/vehicle</td>
</tr>
<tr>
<td colspan="1" rowspan="1"></td>
<td colspan="1" rowspan="1">Normally distributed</td>
<td colspan="1" rowspan="1">Two-way RM ANOVA</td>
<td colspan="1" rowspan="1"><italic>N</italic> = 12per group</td>
<td colspan="1" rowspan="1">Genotype: <italic>p</italic> = 0.0106</td>
</tr>
<tr>
<td colspan="1" rowspan="1">WT veh vs <italic>Fmr1</italic> KO veh</td>
<td colspan="1" rowspan="1">Normally distributed</td>
<td colspan="1" rowspan="1">Sidak’s <italic>post hoc</italic></td>
<td colspan="1" rowspan="1"><italic>N</italic> = 12per group</td>
<td colspan="1" rowspan="1">CI: –0.2916 to –0.06786, <italic>p</italic> = 0.0032</td>
</tr>
<tr>
<td colspan="1" rowspan="1">WT 50 μM lovastatin vs <italic>Fmr1</italic> KO 50 μM lovastatin</td>
<td colspan="1" rowspan="1">Normally distributed</td>
<td colspan="1" rowspan="1">Sidak’s <italic>post hoc</italic></td>
<td colspan="1" rowspan="1"><italic>N</italic> = 12per group</td>
<td colspan="1" rowspan="1">CI: –0.1716 to 0.05214, <italic>p</italic> = 0.3516</td>
</tr>
<tr>
<td colspan="1" rowspan="1"><italic>Fmr1</italic> KO vehicle vs <italic>Fmr1</italic> KO 50 μM lovastatin</td>
<td colspan="1" rowspan="1">Normally distributed</td>
<td colspan="1" rowspan="1">Sidak’s <italic>post hoc</italic></td>
<td colspan="1" rowspan="1"><italic>N</italic> = 12per group</td>
<td colspan="1" rowspan="1">CI: 0.007476 to 0.2312, <italic>p</italic> = 0.0368</td>
</tr>
<tr>
<td align="char" char="–" colspan="5" rowspan="1">
<xref ref-type="fig" rid="F1">Figure 1<italic>C</italic></xref>, metabolic labelling of protein synthesis with 1–5 μM simvastatin/vehicle</td>
</tr>
<tr>
<td colspan="1" rowspan="1"></td>
<td colspan="1" rowspan="1">Normally distributed</td>
<td colspan="1" rowspan="1">Two-way RM ANOVA</td>
<td colspan="1" rowspan="1"><italic>N</italic> = 10per group</td>
<td colspan="1" rowspan="1">Treatment:<italic>p</italic> &lt; 0.0001, genotype: <italic>p</italic> = 0.0294</td>
</tr>
<tr>
<td colspan="1" rowspan="1">WT veh vs KO veh</td>
<td colspan="1" rowspan="1">Normally distributed</td>
<td colspan="1" rowspan="1">Sidak’s <italic>post hoc</italic></td>
<td colspan="1" rowspan="1"><italic>N</italic> = 10per group</td>
<td colspan="1" rowspan="1">CI: –0.3188 to 0.09835, <italic>p</italic> = 0.3451</td>
</tr>
<tr>
<td colspan="1" rowspan="1">WT veh vs KO veh</td>
<td colspan="1" rowspan="1">Normally distributed</td>
<td colspan="1" rowspan="1">Paired <italic>t</italic> test</td>
<td colspan="1" rowspan="1"><italic>N</italic> = 10per group</td>
<td colspan="1" rowspan="1">CI: 0.008558 to 0.2119, <italic>p</italic> = 0.0366</td>
</tr>
<tr>
<td colspan="1" rowspan="1">WT veh vs WT 5 μM simvastatin</td>
<td colspan="1" rowspan="1">Normally distributed</td>
<td colspan="1" rowspan="1">Sidak’s <italic>post hoc</italic></td>
<td colspan="1" rowspan="1"><italic>N</italic> = 10per group</td>
<td colspan="1" rowspan="1">CI: –0.7435 to –0.3263, <italic>p</italic> = 0.0001</td>
</tr>
<tr>
<td colspan="1" rowspan="1"><italic>Fmr1</italic> KO veh vs <italic>Fmr1</italic> KO 5 μM simvastatin</td>
<td colspan="1" rowspan="1">Normally distributed</td>
<td colspan="1" rowspan="1">Sidak’s <italic>post hoc</italic></td>
<td colspan="1" rowspan="1"><italic>N</italic> = 10per group</td>
<td colspan="1" rowspan="1">CI: –0.8045 to –0.3873, <italic>p</italic> &lt; 0.0001</td>
</tr>
<tr>
<td align="char" char="–" colspan="5" rowspan="1">
<xref ref-type="fig" rid="F1">Figure 1<italic>D</italic></xref>, metabolic labelling of protein synthesis with 0.1–0.5 μM simvastatin/vehicle</td>
</tr>
<tr>
<td colspan="1" rowspan="1"></td>
<td colspan="1" rowspan="1">Normally distributed</td>
<td colspan="1" rowspan="1">Two-way RM ANOVA</td>
<td colspan="1" rowspan="1"><italic>N</italic> = 9per group</td>
<td colspan="1" rowspan="1">Treatment: <italic>p</italic> &lt; 0.0001, genotype: <italic>p</italic> = 0.0068</td>
</tr>
<tr>
<td colspan="1" rowspan="1">WT veh vs <italic>Fmr1</italic> KO veh</td>
<td colspan="1" rowspan="1">Normally distributed</td>
<td colspan="1" rowspan="1">Sidak’s <italic>post hoc</italic></td>
<td colspan="1" rowspan="1"><italic>N</italic> = 9per group</td>
<td colspan="1" rowspan="1">CI: –0.2483 to –0.06400, <italic>p</italic> = 0.0005</td>
</tr>
<tr>
<td colspan="1" rowspan="1">WT veh vs WT 0.3 μM simvastatin</td>
<td colspan="1" rowspan="1">Normally distributed</td>
<td colspan="1" rowspan="1">Sidak’s <italic>post hoc</italic></td>
<td colspan="1" rowspan="1"><italic>N</italic> = 9per group</td>
<td colspan="1" rowspan="1">CI: –0.2760 to –0.07980, <italic>p</italic> = 0.0002</td>
</tr>
<tr>
<td colspan="1" rowspan="1">WT veh vs WT 0.5 μM simvastatin</td>
<td colspan="1" rowspan="1">Normally distributed</td>
<td colspan="1" rowspan="1">Sidak’s <italic>post hoc</italic></td>
<td colspan="1" rowspan="1"><italic>N</italic> = 9per group</td>
<td colspan="1" rowspan="1">CI: –0.3394 to –0.1432,<italic>p</italic> &lt; 0.0001</td>
</tr>
<tr>
<td colspan="1" rowspan="1"><italic>Fmr1</italic> KO veh vs <italic>Fmr1</italic> KO 0.3 μM simvastatin</td>
<td colspan="1" rowspan="1">Normally distributed</td>
<td colspan="1" rowspan="1">Sidak’s <italic>post hoc</italic></td>
<td colspan="1" rowspan="1"><italic>N</italic> = 9per group</td>
<td colspan="1" rowspan="1">CI: –0.2334 to –0.03724,<italic>p</italic> = 0.0035</td>
</tr>
<tr>
<td colspan="1" rowspan="1"><italic>Fmr1</italic> KO veh vs <italic>Fmr1</italic> KO 0.5 μM simvastatin</td>
<td colspan="1" rowspan="1">Normally distributed</td>
<td colspan="1" rowspan="1">Sidak’s <italic>post hoc</italic></td>
<td colspan="1" rowspan="1"><italic>N</italic> = 9per group</td>
<td colspan="1" rowspan="1">CI: –0.3121 to –0.1159,<italic>p</italic> &lt; 0.0001</td>
</tr>
<tr>
<td colspan="1" rowspan="1">WT 0.1 μM simvastatin vs <italic>Fmr1</italic> KO 0.1 μM simvastatin</td>
<td colspan="1" rowspan="1">Normally distributed</td>
<td colspan="1" rowspan="1">Sidak’s <italic>post hoc</italic></td>
<td colspan="1" rowspan="1"><italic>N</italic> = 9per group</td>
<td colspan="1" rowspan="1">CI: –0.1874 to –0.003152,<italic>p</italic> = 0.0406</td>
</tr>
<tr>
<td colspan="1" rowspan="1">WT 0.3 μM simvastatin vs <italic>Fmr1</italic> KO 0.3 μM simvastatin</td>
<td colspan="1" rowspan="1">Normally distributed</td>
<td colspan="1" rowspan="1">Sidak’s <italic>post hoc</italic></td>
<td colspan="1" rowspan="1"><italic>N</italic> = 9per group</td>
<td colspan="1" rowspan="1">CI: –0.2057 to –0.02143,<italic>p</italic> = 0.0115</td>
</tr>
<tr>
<td colspan="1" rowspan="1">WT 0.5 μM simvastatin vs <italic>Fmr1</italic> KO 0.5 μM simvastatin</td>
<td colspan="1" rowspan="1">Normally distributed</td>
<td colspan="1" rowspan="1">Sidak’s <italic>post hoc</italic></td>
<td colspan="1" rowspan="1"><italic>N</italic> = 9per group</td>
<td colspan="1" rowspan="1">CI: –0.2210 to –0.03669,<italic>p</italic> = 0.0038</td>
</tr>
<tr>
<td align="center" colspan="5" rowspan="1"><xref ref-type="fig" rid="F2">Figure 2<italic>B</italic></xref>, phospho/total ERK1/2 with 50 μM lovastatin/vehicle</td>
</tr>
<tr>
<td colspan="1" rowspan="1"></td>
<td colspan="1" rowspan="1">Normally distributed</td>
<td colspan="1" rowspan="1">Two-way RM ANOVA</td>
<td colspan="1" rowspan="1"><italic>N</italic> = 19per group</td>
<td colspan="1" rowspan="1">Genotype: <italic>p</italic> = 0.0146</td>
</tr>
<tr>
<td align="char" char="–" colspan="5" rowspan="1">(Continued)</td>
</tr>
<tr>
<td colspan="1" rowspan="1">WT veh vs <italic>Fmr1</italic> KO veh</td>
<td colspan="1" rowspan="1">Normally distributed</td>
<td colspan="1" rowspan="1">Sidak’s <italic>post hoc</italic></td>
<td colspan="1" rowspan="1"><italic>N</italic> = 19per group</td>
<td colspan="1" rowspan="1">CI: –0.02577 to 0.1893,<italic>p</italic> = 0.1539</td>
</tr>
<tr>
<td colspan="1" rowspan="1"><italic>Fmr1</italic> KO veh vs <italic>Fmr1</italic> KO lovastatin</td>
<td colspan="1" rowspan="1">Normally distributed</td>
<td colspan="1" rowspan="1">Sidak’s <italic>post hoc</italic></td>
<td colspan="1" rowspan="1"><italic>N</italic> = 19per group</td>
<td colspan="1" rowspan="1">CI: 0.04797 to 0.2630,<italic>p</italic> = 0.0048</td>
</tr>
<tr>
<td align="char" char="–" colspan="5" rowspan="1"><xref ref-type="fig" rid="F2">Figure 2<italic>C</italic></xref>, phospho/total ERK1/2 with 0.1–0.5 μM simvastatin/vehicle</td>
</tr>
<tr>
<td colspan="1" rowspan="1"></td>
<td colspan="1" rowspan="1">Normally distributed</td>
<td colspan="1" rowspan="1">Two-way RM ANOVA</td>
<td colspan="1" rowspan="1"><italic>N</italic> = 11per group</td>
<td colspan="1" rowspan="1">Genotype: <italic>p</italic> = 0.7010, treatment: <italic>p</italic> = 0.8761</td>
</tr>
<tr>
<td align="char" char="–" colspan="5" rowspan="1">
<xref ref-type="fig" rid="F2">Figure 2<italic>D</italic></xref>, phospho/total p70S6K with 0.1–0.5 μM simvastatin/vehicle</td>
</tr>
<tr>
<td colspan="1" rowspan="1"></td>
<td colspan="1" rowspan="1">Normally distributed</td>
<td colspan="1" rowspan="1">Two-way RM ANOVA</td>
<td colspan="1" rowspan="1"><italic>N</italic> = 10per group</td>
<td colspan="1" rowspan="1">Genotype: <italic>p</italic> = 0.2860, treatment: <italic>p</italic> = 0.6206</td>
</tr>
<tr>
<td align="center" colspan="5" rowspan="1"><xref ref-type="fig" rid="F3">Figure 3<italic>B</italic></xref>, AGS incidence with 3 mg/kg simvastatin</td>
</tr>
<tr>
<td colspan="1" rowspan="1">WT veh vs <italic>Fmr1</italic> KO veh</td>
<td colspan="1" rowspan="1">Non-normal distribution</td>
<td colspan="1" rowspan="1">Two-tailed Fisher’s exact test</td>
<td colspan="1" rowspan="1"><italic>N</italic> = 12per group</td>
<td colspan="1" rowspan="1">CI: 0.002672 to 0.3437, <italic>p</italic> = 0.0028</td>
</tr>
<tr>
<td colspan="1" rowspan="1">WT simvastatin vs <italic>Fmr1</italic> KO simvastatin</td>
<td colspan="1" rowspan="1">Non-normal distribution</td>
<td colspan="1" rowspan="1">Two-tailed Fisher’s exact test</td>
<td colspan="1" rowspan="1"><italic>N</italic> = 12per group</td>
<td colspan="1" rowspan="1">CI: 0.002918 to 0.3808, <italic>p</italic> = 0.0028</td>
</tr>
<tr>
<td colspan="1" rowspan="1"><italic>Fmr1</italic> KO veh vs <italic>Fmr1</italic> KO simvastatin</td>
<td colspan="1" rowspan="1">Non-normal distribution</td>
<td colspan="1" rowspan="1">Two-tailed Fisher’s exact test</td>
<td colspan="1" rowspan="1"><italic>N</italic> = 12per group</td>
<td colspan="1" rowspan="1">CI: 0.1915 to 5.221, <italic>p</italic> &gt; 0.9999</td>
</tr>
<tr>
<td align="center" colspan="5" rowspan="1"><xref ref-type="fig" rid="F3">Figure 3<italic>C</italic></xref>, AGS severity distribution scores with 3 mg/kg simvastatin</td>
</tr>
<tr>
<td colspan="1" rowspan="1">WT veh vs <italic>Fmr1</italic> KO veh</td>
<td colspan="1" rowspan="1">Non-normal distribution</td>
<td colspan="1" rowspan="1">Mann–Whitney test</td>
<td colspan="1" rowspan="1"><italic>N</italic> = 12per group</td>
<td colspan="1" rowspan="1">CI: 0.000 to 2.000, <italic>p</italic> = 0.0028</td>
</tr>
<tr>
<td colspan="1" rowspan="1"><italic>Fmr1</italic> KO veh vs <italic>Fmr1</italic> KO simvastatin</td>
<td colspan="1" rowspan="1">Non-normal distribution</td>
<td colspan="1" rowspan="1">Mann–Whitney test</td>
<td colspan="1" rowspan="1"><italic>N</italic> = 12per group</td>
<td colspan="1" rowspan="1">CI: –1.000 to 1.000, <italic>p</italic> = 0.9510</td>
</tr>
<tr>
<td align="center" colspan="5" rowspan="1"><xref ref-type="fig" rid="F3">Figure 3<italic>D</italic></xref>, AGS latency with 3 mg/kg simvastatin</td>
</tr>
<tr>
<td colspan="1" rowspan="1"><italic>Fmr1</italic> KO veh vs <italic>Fmr1</italic> KO simvastatin</td>
<td colspan="1" rowspan="1">Normally distributed</td>
<td colspan="1" rowspan="1">Unpaired two-tailed <italic>t</italic> test</td>
<td colspan="1" rowspan="1"><italic>N</italic> = 12per group</td>
<td colspan="1" rowspan="1">CI: –11.56 to 43.11,<italic>p</italic> = 0.2388</td>
</tr>
<tr>
<td align="center" colspan="5" rowspan="1"><xref ref-type="fig" rid="F3">Figure 3<italic>E</italic></xref>, AGS incidence with 50 mg/kg simvastatin</td>
</tr>
<tr>
<td colspan="1" rowspan="1">WT veh vs <italic>Fmr1</italic> KO veh</td>
<td colspan="1" rowspan="1">Non-normal distribution</td>
<td colspan="1" rowspan="1">Two-tailed Fisher’s exact test</td>
<td colspan="1" rowspan="1">KO veh: <italic>n</italic> = 14WT veh: <italic>n</italic> = 12</td>
<td colspan="1" rowspan="1">CI: 0.004960 to 0.5143, <italic>p</italic> = 0.0053</td>
</tr>
<tr>
<td colspan="1" rowspan="1">WT simvastatin vs <italic>Fmr1</italic> KO simvastatin</td>
<td colspan="1" rowspan="1">Non-normal distribution</td>
<td colspan="1" rowspan="1">Two-tailed Fisher’s exact test</td>
<td colspan="1" rowspan="1">KO simva: <italic>n</italic> = 11WT simva:<italic>n</italic> = 13</td>
<td colspan="1" rowspan="1">CI: 0.006556 to 0.7356, <italic>p</italic> = 0.0233</td>
</tr>
<tr>
<td colspan="1" rowspan="1"><italic>Fmr1</italic> KO veh vs <italic>Fmr1</italic> KO simvastatin</td>
<td colspan="1" rowspan="1">Non-normal distribution</td>
<td colspan="1" rowspan="1">Two-tailed Fisher’s exact test</td>
<td colspan="1" rowspan="1">KO veh: <italic>n</italic> = 14 KO simva: <italic>n</italic> = 11</td>
<td colspan="1" rowspan="1">CI: 0.2988 to 7.531, <italic>p</italic> = 0.6968</td>
</tr>
<tr>
<td align="center" colspan="5" rowspan="1"><xref ref-type="fig" rid="F3">Figure 3<italic>F</italic></xref>, AGS severity scores with 50 mg/kg simvastatin</td>
</tr>
<tr>
<td colspan="1" rowspan="1">WT veh vs <italic>Fmr1</italic> KO veh</td>
<td colspan="1" rowspan="1">Non-normal distribution</td>
<td colspan="1" rowspan="1">Mann–Whitney test</td>
<td colspan="1" rowspan="1">KO veh: <italic>n</italic> = 14WT veh: <italic>n</italic> = 12</td>
<td colspan="1" rowspan="1">CI: 0.000 to 3.000, <italic>p</italic> = 0.0036</td>
</tr>
<tr>
<td colspan="1" rowspan="1"><italic>Fmr1</italic> KO veh vs <italic>Fmr1</italic> KO simvastatin</td>
<td colspan="1" rowspan="1">Non-normal distribution</td>
<td colspan="1" rowspan="1">Mann–Whitney test</td>
<td colspan="1" rowspan="1">KO veh: <italic>n</italic> = 14 KO simva: <italic>n</italic> = 11</td>
<td colspan="1" rowspan="1">CI: –3.000 to 0.000, <italic>p</italic> = 0.2254</td>
</tr>
<tr>
<td align="center" colspan="5" rowspan="1"><xref ref-type="fig" rid="F3">Figure 3<italic>G</italic></xref>, AGS latency with 50 mg/kg simvastatin</td>
</tr>
<tr>
<td colspan="1" rowspan="1"><italic>Fmr1</italic> KO veh vs <italic>Fmr1</italic> KO simvastatin</td>
<td colspan="1" rowspan="1">Normally distributed</td>
<td colspan="1" rowspan="1">Unpaired two-tailed <italic>t</italic> test</td>
<td colspan="1" rowspan="1">KO veh: <italic>n</italic> = 14 KO simva: <italic>n</italic> = 11</td>
<td colspan="1" rowspan="1">CI: –11.41 to 8.739,<italic>p</italic> = 0.7794</td>
</tr>
<tr>
<td align="center" colspan="5" rowspan="1"><xref ref-type="fig" rid="F3">Figure 3<italic>H</italic></xref>, AGS incidence with 100 mg/kg lovastatin</td>
</tr>
<tr>
<td colspan="1" rowspan="1">WT veh vs <italic>Fmr1</italic> KO veh</td>
<td colspan="1" rowspan="1">Non-normal distribution</td>
<td colspan="1" rowspan="1">Two-tailed Fisher’s exact test</td>
<td colspan="1" rowspan="1">KO veh: <italic>n</italic> = 16WT veh: <italic>n</italic> = 15</td>
<td colspan="1" rowspan="1">CI: 0.01126 to 0.4341, <italic>p</italic> = 0.0032</td>
</tr>
<tr>
<td colspan="1" rowspan="1">WT lovastatin vs <italic>Fmr1</italic> KO lovastatin</td>
<td colspan="1" rowspan="1">Non-normal distribution</td>
<td colspan="1" rowspan="1">Two-tailed Fisher’s exact test</td>
<td colspan="1" rowspan="1">KO lova: <italic>n</italic> = 14WT lova:<italic>n</italic> = 17</td>
<td colspan="1" rowspan="1">CI: 0.06948 to 3.440, <italic>p</italic> = 0.6358</td>
</tr>
<tr>
<td align="char" char="–" colspan="5" rowspan="1">(Continued)</td>
</tr>
<tr>
<td colspan="1" rowspan="1"><italic>Fmr1</italic> KO veh vs <italic>Fmr1</italic> KO lovastatin</td>
<td colspan="1" rowspan="1">Non-normal distribution</td>
<td colspan="1" rowspan="1">Two-tailed Fisher’s exact test</td>
<td colspan="1" rowspan="1">KO veh: <italic>n</italic> = 16 KO lova: <italic>n</italic> = 14</td>
<td colspan="1" rowspan="1">CI: 1.538 to 42.32, <italic>p</italic> = 0.0136</td>
</tr>
<tr>
<td align="center" colspan="5" rowspan="1"><xref ref-type="fig" rid="F3">Figure 3<italic>I</italic></xref>, AGS severity distribution scores with 100 mg/kg lovastatin</td>
</tr>
<tr>
<td colspan="1" rowspan="1">WT veh vs <italic>Fmr1</italic> KO veh</td>
<td colspan="1" rowspan="1">Non-normal distribution</td>
<td colspan="1" rowspan="1">Mann–Whitney test</td>
<td colspan="1" rowspan="1">KO veh: <italic>n</italic> = 16<italic>n</italic> = WT veh: <italic>n</italic> = 15</td>
<td colspan="1" rowspan="1">CI: 0.000 to 3.000, <italic>p</italic> = 0.0064</td>
</tr>
<tr>
<td colspan="1" rowspan="1"><italic>Fmr1</italic> KO veh vs <italic>Fmr1</italic> KO lovastatin</td>
<td colspan="1" rowspan="1">Non-normal distribution</td>
<td colspan="1" rowspan="1">Mann–Whitney test</td>
<td colspan="1" rowspan="1">KO veh: <italic>n</italic> = 16 KO lova: <italic>n</italic> = 14</td>
<td colspan="1" rowspan="1">CI: –3.000 to 0.000, <italic>p</italic> = 0.0204</td>
</tr>
<tr>
<td align="center" colspan="5" rowspan="1"><xref ref-type="fig" rid="F3">Figure 3<italic>J</italic></xref>, AGS latency with 100 mg/kg lovastatin</td>
</tr>
<tr>
<td colspan="1" rowspan="1"><italic>Fmr1</italic> KO veh vs <italic>Fmr1</italic> KO simvastatin</td>
<td colspan="1" rowspan="1">Normally distributed</td>
<td colspan="1" rowspan="1">Unpaired two-tailed <italic>t</italic> test</td>
<td colspan="1" rowspan="1">KO veh: <italic>n</italic> = 16 KO lova: <italic>n</italic> = 14</td>
<td colspan="1" rowspan="1">CI: 3.595 to 31.07,<italic>p</italic> = 0.0176</td>
</tr>
</tbody>
</table>
</table-wrap>
</sec>
</sec>
<sec id="s4" sec-type="results">
<title>Results</title>
<sec id="s4A">
<title>Lovastatin, but not simvastatin, normalizes excessive protein synthesis in the <italic>Fmr1<sup>-/y</sup></italic> hippocampus</title>
<p>Previous work shows that lovastatin normalizes excessive protein synthesis in the <italic>Fmr1<sup>-/y</sup></italic> hippocampus through reduction of Ras-ERK1/2 activation, which corrects epileptogenic phenotypes (<xref ref-type="bibr" rid="B34">Osterweil et al., 2013</xref>). To examine whether the same effect is seen with simvastatin, we used a metabolic labeling assay in hippocampal slices designed to assess protein synthesis in an intact preparation under physiologic conditions. Hippocampal slices were prepared from juvenile WT and <italic>Fmr1<sup>-/y</sup></italic> littermates, blind to genotype, and allowed to recover in oxygenating ACSF. Following this, slices were preincubated with Actinomycin D to block transcription, and new protein synthesis was labeled through incorporation of <sup>35</sup>S-labeled methionine/cysteine mix (<xref ref-type="fig" rid="F1">Fig. 1<italic>A</italic></xref>).</p>
<fig fig-type="figure" id="F1" orientation="portrait" position="float">
<label>Figure 1.</label>
<caption>
<p>
Simvastatin exaggerates excessive protein synthesis in the <italic>Fmr1<sup>-/y</sup></italic> hippocampus. Slices were prepared from WT and <italic>Fmr1<sup>-/y</sup></italic> hippocampi and incubated in vehicle, lovastatin, or simvastatin at different concentrations. <bold><italic>A</italic></bold>, Schematic shows time course for metabolic labeling experiments of hippocampal slices. <bold><italic>B</italic></bold>, Lovastatin significantly decreases protein synthesis in <italic>Fmr1<sup>-/y</sup></italic> slices to WT levels (ANOVA genotype *<italic>p</italic> = 0.0106; Sidak’s WT veh vs KO veh *<italic>p</italic> = 0.0032, KO veh vs KO lova *<italic>p</italic> = 0.0368; <italic>n</italic> = 12). <bold><italic>C</italic></bold>, Simvastatin raises protein synthesis in both WT and <italic>Fmr1<sup>-/y</sup></italic> slices at 5 μM (ANOVA treatment *<italic>p</italic> &lt; 0.0001, genotype *<italic>p</italic> = 0.0294; Sidak’s WT veh vs 5 μM *<italic>p</italic> = 0.0001, KO veh vs 5 μM *<italic>p</italic> &lt; 0.0001; <italic>n</italic> = 10). <bold><italic>D</italic></bold>, Simvastatin raises protein synthesis at 0.1–0.5 μM, exaggerating the excessive protein synthesis phenotype (ANOVA treatment *<italic>p</italic> &lt; 0.0001, genotype *<italic>p</italic> = 0.0068; Sidak’s WT veh vs 0.3 μM *<italic>p</italic> = 0.0002, WT veh vs 0.5 μM *<italic>p</italic> &lt; 0.0001, KO veh vs 0.3 μM *<italic>p</italic> = 0.0035, KO veh vs 0.5 μM *<italic>p</italic> &lt; 0.0001, WT veh vs KO veh *<italic>p</italic> = 0.0005, WT 0.1 μM vs KO 0.1 μM *<italic>p</italic> = 0.0406, WT 0.3 μM vs KO 0.3 μM *<italic>p</italic> = 0.0115, WT 0.5 μM vs KO 0.5 μM *<italic>p</italic> = 0.0038; <italic>n</italic> = 9). Representative samples were run on SDS-PAGE gels and transferred to membranes. Example phosphorimages of <sup>35</sup>S-labeled proteins and total protein staining of the same membrane are shown. Error bars = SEM. <italic>N</italic> = littermate pairs. <italic>Figure Contributions</italic>: Melania Muscas and Susana R. Louros performed the experiments and analyzed the data.</p>
</caption>
<graphic xlink:href="enu0031929550001"></graphic>
</fig>
<p>Previous experiments tested a range of 10–50 µM lovastatin and showed that 50 µM was effective in normalizing protein synthesis in the <italic>Fmr1<sup>-/y</sup></italic> hippocampus (<xref ref-type="bibr" rid="B34">Osterweil et al., 2013</xref>). To ensure that we could recapitulate these results, we measured protein synthesis in WT and <italic>Fmr1<sup>-/y</sup></italic> slices ±50 µM lovastatin (<xref ref-type="fig" rid="F1">Fig. 1<italic>B</italic></xref>). As expected, our experiments revealed a significant correction of excessive protein synthesis with lovastatin in the <italic>Fmr1<sup>-/y</sup></italic> mouse (WT veh = 100 ± 1.48%, WT lova = 100.06 ± 4.87%, KO veh = 117.97 ± 4.27%, KO lova = 106.04 ± 4.93%; WT vs KO veh <italic>p</italic> = 0.0032, KO veh vs lova <italic>p</italic> = 0.0368; <italic>n</italic> = 12). Next, we tested the efficacy of simvastatin using the same assay system. As simvastatin is twice as potent as lovastatin with respect to reducing plasma LDL cholesterol levels in patients, we tested a lower dose range of simvastatin in our metabolic labeling assay (<xref ref-type="bibr" rid="B46">Tsuji et al., 1993</xref>; <xref ref-type="bibr" rid="B16">Jones et al., 1998</xref>; <xref ref-type="bibr" rid="B41">Schaefer et al., 2004</xref>; <xref ref-type="bibr" rid="B31">Neuvonen et al., 2008</xref>). This concentration is consistent with previous studies of simvastatin in cultured neurons (<xref ref-type="bibr" rid="B23">Lim et al., 2006</xref>; <xref ref-type="bibr" rid="B15">Johnson-Anuna et al., 2007</xref>; <xref ref-type="bibr" rid="B26">Mans et al., 2010</xref>). Interestingly, we find that simvastatin treatment not only fails to reduce protein synthesis in the <italic>Fmr1<sup>-/y</sup></italic> hippocampus, it causes a significant increase in both WT and <italic>Fmr1<sup>-/y</sup></italic> slices at 5 µM (WT vehicle = 100 ± 2.70%, WT 5 μM = 153.5 ± 6.32%, KO vehicle = 111 ± 4.27%, KO 5 μM = 170.60 ± 9.43%; WT veh vs 5 μM <italic>p</italic> = 0.0001, KO veh vs 5 μM <italic>p</italic> &lt; 0.0001; <italic>n</italic> = 10; <xref ref-type="fig" rid="F1">Fig. 1<italic>C</italic></xref>).</p>
<p>This puzzling increase in protein synthesis led us to wonder whether a reduced concentration of simvastatin might be more appropriate. To test this, we exposed slices to vehicle or simvastatin at concentrations of 0.1–0.5 µM. Surprisingly, we find that even at these lower concentrations simvastatin causes a dose-dependent increase in protein synthesis, worsening the <italic>Fmr1<sup>-/y</sup></italic> phenotype (WT veh = 100 ± 2.21%, WT 0.1 μM = 106.99 ± 3.51%, WT 0.3 μM = 117.79 ± 4.08%, WT 0.5 μM = 124.13 ± 4.23%, KO veh = 115.61 ± 3.48%, KO 0.1 μM = 116.52 ± 2.21%, KO 0.3 μM = 129.15 ± 3.99%, KO 0.5 μM = 137.01 ± 3.08%; WT veh vs 0.3 μM <italic>p</italic> = 0.0002, WT veh vs 0.5 μM <italic>p</italic> &lt; 0.0001, KO veh vs 0.3 μM <italic>p</italic> = 0.0035, KO veh vs 0.5 μM <italic>p</italic> &lt; 0.0001; <italic>n</italic> = 9; <xref ref-type="fig" rid="F1">Fig. 1<italic>D</italic></xref>). These results show that unlike lovastatin, simvastatin does not correct excessive protein synthesis in the <italic>Fmr1<sup>-/y</sup></italic> hippocampus.</p>
</sec>
<sec id="s4B">
<title>Lovastatin, but not simvastatin, reduces ERK1/2 activation</title>
<p>Our metabolic labeling experiments show that 50 µM lovastatin reduces protein synthesis in the <italic>Fmr1<sup>-/y</sup></italic> hippocampus by 15–20% (<xref ref-type="fig" rid="F1">Fig. 1<italic>B</italic></xref>). Conversely, 0.5 µM simvastatin causes a 15–20% increase in protein synthesis in the <italic>Fmr1<sup>-/y</sup></italic> hippocampus (<xref ref-type="fig" rid="F1">Fig. 1<italic>D</italic></xref>). Given the opposite effect of lovastatin and simvastatin on protein synthesis, we wondered whether these compounds acted differently on the ERK1/2 and mTOR translation control signaling pathways (<xref ref-type="fig" rid="F2">Fig. 2<italic>A</italic></xref>). To confirm the same lovastatin treatment that reduces excess protein synthesis in the <italic>Fmr1<sup>-/y</sup></italic> also reduces ERK1/2 activation, we incubated slices in vehicle or 50 µM lovastatin and performed quantitative immunoblotting for p-ERK1/2 (<xref ref-type="fig" rid="F2">Fig. 2<italic>B</italic></xref>; Extended Data <xref ref-type="supplementary-material" rid="fig2-1">Fig. 2-1</xref>). Our results confirm that 50 µM lovastatin significantly reduces p-ERK1/2 in <italic>Fmr1<sup>-/y</sup></italic> slices as previously reported (WT veh = 100 ± 4.32%, WT lova = 99.28 ± 4.42%, KO veh = 91.83 ± 4.74%, KO lova = 76.28 ± 3.76%; KO veh vs lova <italic>p</italic> = 0.0048; <italic>n</italic> = 19).</p>
<fig fig-type="figure" id="F2" orientation="portrait" position="float">
<label>Figure 2.</label>
<caption>
<p>Simvastatin does not reduce ERK1/2 or mTORC1 activation in the <italic>Fmr1<sup>-/y</sup></italic> hippocampus. <bold><italic>A</italic></bold>, Diagram shows the potential impact of simvastatin on Ras-ERK1/2 and Rheb-mTOR-signaling pathways. <bold><italic>B</italic></bold>, <italic>Fmr1<sup>-/y</sup></italic> slices incubated with 50 µM lovastatin show a significant reduction in ERK1/2 phosphorylation (ANOVA genotype *<italic>p</italic> = 0.0146; Sidak’s KO veh vs KO lova *<italic>p</italic> = 0.0048; <italic>n</italic> = 19). <bold><italic>C</italic></bold>, Simvastatin treatment does not reduce ERK1/2 phosphorylation in <italic>Fmr1<sup>-/y</sup></italic> or WT slices (ANOVA treatment <italic>p</italic> = 0.8761, genotype <italic>p</italic> = 0.7010; <italic>n</italic> = 11). <bold><italic>D</italic></bold>, Simvastatin treatment does not reduce phosphorylation of p70S6K in WT or <italic>Fmr1<sup>-/y</sup></italic> slices (ANOVA treatment <italic>p</italic> = 0.6206, genotype <italic>p</italic> = 0.2860; <italic>n</italic> = 10). Representative bands were cropped from original blots as indicated by blank spaces. Original blots are shown in Extended Data <xref ref-type="supplementary-material" rid="fig2-1">Figure 2-1</xref>. Error bars = SEM. <italic>N</italic> = littermate pairs. <italic>Figure Contributions</italic>: Melania Muscas performed the experiments and analyzed the data.</p>
</caption>
<graphic xlink:href="enu0031929550002"></graphic>
</fig>
<p>Next, to test whether simvastatin had a differential impact on ERK1/2 signaling at the same concentration that causes a 15–20% increase in protein synthesis, we repeated our immunoblotting analysis on slices exposed to vehicle or 0.1–0.5 µM simvastatin. In contrast to lovastatin, our results show that simvastatin has no significant impact on p-ERK1/2 in either WT or <italic>Fmr1<sup>-/y</sup></italic> slices at any dose tested (WT veh = 100 ± 4.51%, WT 0.1 μM = 102.87 ± 3.42%, WT 0.3 μM = 108.45 ± 4.10%, WT 0.5 μM = 101.01% ± 2.09%, KO veh = 105.63 ± 4.97%, KO 0.1 μM = 98.94 ± 4.46%, KO 0.3 μM = 94.71 ± 4.53%, KO 0.5 μM = 106.93 ± 3.65%; <italic>n</italic> = 11; <xref ref-type="fig" rid="F2">Fig. 2<italic>C</italic></xref>; Extended Data <xref ref-type="supplementary-material" rid="fig2-1">Fig. 2-1</xref>). This suggests that simvastatin neither activates nor inhibits the ERK1/2 pathway under conditions where it increases protein synthesis.</p>
<p>Although our previous study with lovastatin showed no effect of lovastatin on mTOR activation as assessed by phosphorylation of p70S6K, we wondered whether simvastatin had an observable impact on this pathway. To investigate, we immunoblotted for p-p70S6K in WT and <italic>Fmr1<sup>-/y</sup></italic> slices treated with 0.1–0.5 µM simvastatin. Our results show that p70S6K activation is unchanged in slices treated with 0.1–0.5 µM simvastatin (WT veh = 100 ± 11.14%, WT 0.1 μM = 112.94 ± 10.25%, WT 0.3 μM = 110.66 ± 9.47%, WT 0.5 μM = 98.89 ± 4.72%, KO veh = 92.87 ± 4.49%, KO 0.1 μM = 85.37% ± 11.82%, KO 0.3 μM = 101.71% ± 10.37%, KO 0.5 μM = 92.53% ± 10.64%; <italic>n</italic> = 10; <xref ref-type="fig" rid="F2">Fig. 2<italic>D</italic></xref>; Extended Data <xref ref-type="supplementary-material" rid="fig2-1">Fig. 2-1</xref>). Together, these experiments show that unlike lovastatin, simvastatin does not affect the activation of ERK1/2, nor does it alter the mTORC1-p70S6K pathway.</p>
</sec>
<sec id="s4C">
<title>Lovastatin, but not simvastatin, corrects the AGS phenotype in the <italic>Fmr1<sup>-/y</sup></italic> mouse</title>
<p>Our work <italic>in vitro</italic> shows that simvastatin does not correct the ERK1/2-stimulated excess in protein synthesis in the <italic>Fmr1<sup>-/y</sup></italic> hippocampus, suggesting that it may not have the same efficacy as lovastatin in ameliorating pathologic phenotypes. To directly test this, we performed a side-by-side analysis of the effect of lovastatin versus simvastatin on the incidence of AGS in the <italic>Fmr1<sup>-/y</sup></italic> mouse. Although the AGS phenotype is seen in <italic>Fmr1<sup>-/y</sup></italic> mice bred on multiple mouse background strains, a more robust phenotype is observed in mice bred on the FVB strain or a C57Bl6/J x FVB hybrid strain (<xref ref-type="bibr" rid="B52">Yan et al., 2004</xref>, <xref ref-type="bibr" rid="B53">2005</xref>). Therefore, we used <italic>Fmr1<sup>-/y</sup></italic> and littermate WT mice bred on a C57Bl6/J x FVB hybrid strain for our AGS study. Importantly, lovastatin corrects the AGS phenotype in <italic>Fmr1<sup>-/y</sup></italic> bred on both C57BL/6J and FVB strains, suggesting the rescue is not dictated by background genetics (<xref ref-type="bibr" rid="B34">Osterweil et al., 2013</xref>).</p>
<p>To test whether simvastatin could similarly correct the AGS phenotype, we injected <italic>Fmr1<sup>-/y</sup></italic> and littermate WT mice with 3 mg/kg simvastatin as described in Materials and Methods. We used the lactone prodrug version of simvastatin administered to human patients, which is hydrolyzed into the active hydroxy acid compound by the liver (<xref ref-type="bibr" rid="B40">Schachter, 2005</xref>). The initial dose of simvastatin was chosen based on previous work showing 1 mg/kg simvastatin reduces epileptogenic activity and neurotoxicity in a kainic acid (KA) rat model of epilepsy (<xref ref-type="bibr" rid="B50">Xie et al., 2011</xref>). Additionally, according to a conversion factor of 0.081 for mouse to human dosing recommended by the Food and Drug Administration (FDA), 3 mg/kg simvastatin in mouse would be equivalent to the 20 mg dose used in humans (<xref ref-type="bibr" rid="B30">Nair and Jacob, 2016</xref>).</p>
<p>Animals were injected with vehicle or simvastatin with the experimenter blind to genotype and treatment, and then left in a quiet environment for 1 h before AGS testing. A 1-h incubation time was chosen based on previous experiments using lovastatin, and on previous pharmacokinetic studies in mice and rats showing that simvastatin peaks in blood at 30 min to 1 h after administration (<xref ref-type="bibr" rid="B48">van de Steeg et al., 2013</xref>; <xref ref-type="bibr" rid="B12">Higgins et al., 2014</xref>; <xref ref-type="bibr" rid="B51">Xu et al., 2014</xref>), and peaks in brain 1 h after administration (<xref ref-type="bibr" rid="B14">Johnson-Anuna et al., 2005</xref>). To induce AGS, animals were transferred to a test chamber and exposed to a 2-min digitized sampling of a personal alarm passed through 50-W speakers at a level of &gt;130 dB. Seizures were recorded at increasing levels of severity as: 1, wild running (uncontrolled and undirected running); 2, clonic seizure (loss of balance with violent spasms on all limbs); and 3, tonic seizure (loss of balance with postural rigidity in limbs and tail; <xref ref-type="fig" rid="F3">Fig. 3<italic>A</italic></xref>). Latency between the onset of the AGS stimulus and seizure was also used as a metric of seizure severity and measured as the number of seconds between the start of the alarm to the first appearance of wild running.</p>
<fig fig-type="figure" id="F3" orientation="portrait" position="float">
<label>Figure 3.</label>
<caption>
<p>Simvastatin does not correct AGS in the <italic>Fmr1<sup>-/y</sup></italic> mouse. <italic>Fmr1<sup>-/y</sup></italic> and littermate WT mice were injected intraperitoneally with vehicle, simvastatin, or lovastatin and tested for AGS. <bold><italic>A</italic></bold>, Schematic shows the experimental timeline and scoring system for AGS testing. <bold><italic>B</italic></bold>, Injection of 3 mg/kg simvastatin does not reduce the incidence of AGS in <italic>Fmr1<sup>-/y</sup></italic> mice (Fisher’s exact test WT vs KO veh *<italic>p</italic> = 0.0028, WT vs KO simva *<italic>p</italic> = 0.0028, KO veh vs simva <italic>p</italic> &gt; 0.999). <bold><italic>C</italic></bold>, Comparison of AGS scores also shows no reduction of seizure severity with 3 mg/kg simvastatin (Mann–Whitney WT vs KO veh *<italic>p</italic> = 0.0028, KO veh vs KO simva <italic>p</italic> = 0.9510). <bold><italic>D</italic></bold>, 3 mg/kg simvastatin does not increase latency to first seizure in <italic>Fmr1<sup>-/y</sup></italic> mice (unpaired <italic>t</italic> test <italic>p</italic> = 0.239). <bold><italic>E</italic></bold>, 50 mg/kg active simvastatin does not reduce AGS incidence in <italic>Fmr1<sup>-/y</sup></italic> mice (Fisher’s exact test WT vs KO veh *<italic>p</italic> = 0.0053, WT vs KO simva *<italic>p</italic> = 0.0233, KO veh vs simva <italic>p</italic> = 0.6968). <bold><italic>F</italic></bold>, AGS severity scores are not significantly reduced with 50 mg/kg simvastatin (Mann–Whitney WT vs KO veh *<italic>p</italic> = 0.0036, KO veh vs KO simva <italic>p</italic> = 0.2254). <bold><italic>G</italic></bold>, Latency to first seizure is not significantly different between vehicle and 50 mg/kg simvastatin-treated <italic>Fmr1<sup>-/y</sup></italic> mice (unpaired <italic>t</italic> test <italic>p</italic> = 0.779). <bold><italic>H</italic></bold>, Injection of 100 mg/kg lovastatin significantly reduces the incidence of AGS in <italic>Fmr1<sup>-/y</sup></italic> mice (Fisher’s exact test WT vs KO veh *<italic>p</italic> = 0.0032, WT vs KO lova <italic>p</italic> = 0.6358, KO veh vs lova *<italic>p</italic> = 0.0136). <bold><italic>I</italic></bold>, Lovastatin reduces severity scores of AGS in <italic>Fmr1<sup>-/y</sup></italic> mice versus vehicle (Mann–Whitney WT vs KO veh *<italic>p</italic> = 0.0064, KO veh vs KO lova *<italic>p</italic> = 0.0204). <bold><italic>J</italic></bold>, Lovastatin treatment significantly increases the latency to first seizure compared to vehicle-treated <italic>Fmr1<sup>-/y</sup></italic> mice (unpaired <italic>t</italic> test KO veh vs lova *<italic>p</italic> = 0.0176). Error bars = SEM. <italic>Figure Contributions</italic>: Melania Muscas performed the experiments and analyzed the data.</p>
</caption>
<graphic xlink:href="enu0031929550003"></graphic>
</fig>
<p>Our results show that vehicle-treated <italic>Fmr1<sup>-/y</sup></italic> mice exhibit a significantly higher incidence of AGS versus WT littermates (WT veh 8%, KO veh 75%, <italic>p</italic> = 0.0028) and a significant increase in seizure severity (WT vs KO veh <italic>p</italic> = 0.0028). However, in contrast to lovastatin, 3 mg/kg simvastatin injection had no significant effect on the incidence of AGS in <italic>Fmr1<sup>-/y</sup></italic> mice (WT veh 8%, WT simva 9%, KO veh 75%, KO simva 75%; WT vs KO simva <italic>p</italic> = 0.0028, KO veh vs simva <italic>p</italic> = 1.000; <xref ref-type="fig" rid="F3">Fig. 3<italic>B</italic></xref>). Comparison of AGS scores showed 3 mg/kg simvastatin was similarly ineffective in reducing seizure severity (KO veh: wild running 1/12, clonic 5/12, tonic 3/12; KO simva: wild running 3/12, clonic 2/12, tonic 4/12; KO veh vs simva <italic>p</italic> = 0.951; <xref ref-type="fig" rid="F3">Fig. 3<italic>C</italic></xref>). Measurements of the latency to first seizure also reveal no significant effect of simvastatin treatment (KO veh = 26.33 ± 3.80 s, KO simva = 42.11 ± 12.32 s, <italic>p</italic> = 0.239; <xref ref-type="fig" rid="F3">Fig. 3<italic>D</italic></xref>). These results suggest simvastatin is not effective in correcting AGS in <italic>Fmr1<sup>-/y</sup></italic> mice.</p>
<p>Although 3 mg/kg is consistent with a simvastatin dose used in previous studies of KA-induced seizure, higher doses of up to 50 mg/kg have also been investigated with respect to neurologic phenotypes in rodents (<xref ref-type="bibr" rid="B39">Ramirez et al., 2011</xref>; <xref ref-type="bibr" rid="B24">Ling and Tejada-Simon, 2016</xref>). Indeed, intraperitoneal injection of 50 mg/kg active simvastatin 24 h and 30 min before seizure induction protects against KA-induced seizures in mice (<xref ref-type="bibr" rid="B39">Ramirez et al., 2011</xref>), and increases learning in a mouse model of Alzheimer’s disease (<xref ref-type="bibr" rid="B20">Li et al., 2006</xref>). To ensure that simvastatin is not effective in correcting the AGS phenotype in <italic>Fmr1<sup>-/y</sup></italic> mice, we repeated our experiments using a high dose of 50 mg/kg. To remove the potential confound of prodrug metabolism, we injected active simvastatin hydroxy acid rather than inactive lactone. In a comparison group, we tested an equipotent 100 mg/kg dose of active lovastatin hydroxy acid that was previously shown to correct AGS in adult <italic>Fmr1<sup>-/y</sup></italic> FVB mice (<xref ref-type="bibr" rid="B34">Osterweil et al., 2013</xref>). Separate groups of <italic>Fmr1<sup>-/y</sup></italic> and WT littermates were injected with 50 mg/kg simvastatin or 100 mg/kg lovastatin (with corresponding vehicle) and AGS testing performed as previously.</p>
<p>Our results show that even at a higher dose, simvastatin does not reduce AGS incidence in <italic>Fmr1<sup>-/y</sup></italic> mice (WT veh 8%, WT simva 8%, KO veh 64%, KO simva 55%; WT vs KO veh <italic>p</italic> = 0.0053, WT vs KO simva <italic>p</italic> = 0.0233, KO veh vs simva <italic>p</italic> = 0.6968; <xref ref-type="fig" rid="F3">Fig. 3<italic>E</italic></xref>). AGS severity is similarly not reduced in simvastatin-treated <italic>Fmr1<sup>-/y</sup></italic> mice as assessed by seizure score (KO veh: wild running 0/14, clonic 1/14, tonic 8/14; KO simva: wild running 0/11, clonic 3/11, tonic 3/11; WT vs KO veh *<italic>p</italic> = 0.0036, KO veh vs KO simva <italic>p</italic> = 0.2254; <xref ref-type="fig" rid="F3">Fig. 3<italic>F</italic></xref>) or latency to seizure onset (KO veh = 27 ± 2.95 s, KO simva = 25.67 ± 3.61 s, <italic>p</italic> = 0.779; <xref ref-type="fig" rid="F3">Fig. 3<italic>G</italic></xref>). In contrast, <italic>Fmr1<sup>-/y</sup></italic> mice injected with 100 mg/kg lovastatin showed a significant reduction in AGS versus vehicle-treated mice (WT veh 13%, WT lova 12%, KO veh 69%, KO lova 21%; WT vs KO veh <italic>p</italic> = 0.0032, KO veh vs lova <italic>p</italic> = 0.0136, WT veh vs KO lova <italic>p</italic> = 0.6513; <xref ref-type="fig" rid="F3">Fig. 3<italic>H</italic></xref>). Additionally, AGS scoring reveals a decrease in the severity of seizures in lovastatin-treated <italic>Fmr1<sup>-/y</sup></italic> mice (KO veh: wild running 0/16, clonic 5/16, tonic 6/16; KO lova: wild running 0/14, clonic 1/14, tonic 2/14; WT vs KO veh *<italic>p</italic> = 0.0064, KO veh vs KO lova *<italic>p</italic> = 0.0204; <xref ref-type="fig" rid="F3">Fig. 3<italic>I</italic></xref>), and an increase in the latency to the first seizure (KO veh = 28 ± 3 s, KO lova = 45.33 ± 4.84 s, KO veh vs lova *<italic>p</italic> = 0.0176; <xref ref-type="fig" rid="F3">Fig. 3<italic>J</italic></xref>). Together, these results show that lovastatin reduces the incidence and severity of AGS in the <italic>Fmr1<sup>-/y</sup></italic>, whereas simvastatin has no effect.</p>
</sec>
</sec>
<sec id="s5" sec-type="discussion">
<title>Discussion</title>
<p>The promising results using lovastatin in FX have led to the suggestion that simvastatin may be similarly effective. In this study, we investigated two core phenotypes in the <italic>Fmr1<sup>-/y</sup></italic> mouse model to test the prediction that simvastatin can be used in place of lovastatin. Our results show that simvastatin not only fails to correct excessive protein synthesis in the <italic>Fmr1<sup>-/y</sup></italic> hippocampus, it worsens this phenotype (<xref ref-type="fig" rid="F1">Fig. 1</xref>). We do not see a reduction of ERK1/2 activation at the concentrations of simvastatin tested (<xref ref-type="fig" rid="F2">Fig. 2</xref>). Moreover, simvastatin does not reduce the incidence or severity of AGS in the <italic>Fmr1<sup>-/y</sup></italic> mouse even at a high dose of 50 mg/kg (<xref ref-type="fig" rid="F3">Fig. 3</xref>). These results suggest that simvastatin should not be assumed to be an effective replacement for lovastatin with respect to correction of <italic>Fmr1<sup>-/y</sup></italic> pathology.</p>
<p>Although we propose the beneficial effect of lovastatin stems from the inhibition of ERK1/2-driven protein synthesis, it is important to note that statins are capable of affecting several biochemical pathways. Beyond the canonical impact on cholesterol biosynthesis, statins also decrease isoprenoid intermediates including farnesyl and geranylgeranyl pyrophosphates that regulate membrane association for many proteins including the small GTPases Ras, Rho, and Rac (<xref ref-type="bibr" rid="B42">Schafer et al., 1989</xref>; <xref ref-type="bibr" rid="B22">Liao and Laufs, 2005</xref>; <xref ref-type="bibr" rid="B32">Nürenberg and Volmer, 2012</xref>; <xref ref-type="bibr" rid="B24">Ling and Tejada-Simon, 2016</xref>). The increase in protein synthesis seen with simvastatin could be linked to altered posttranslational modification of these or other proteins. Indeed, although we see no change in mTORC1-p70S6K signaling, other studies have shown an activation of the PI3 kinase pathway that could be contributing to this effect (<xref ref-type="bibr" rid="B26">Mans et al., 2010</xref>). However, our comparison of lovastatin and simvastatin shows that there is a clear difference in the correction of pathology in the <italic>Fmr1<sup>-/y</sup></italic> model, suggesting that the impact on ERK1/2 is an important factor in terms of pharmacological treatment for FX.</p>
<p>There are many reasons why statins would be an attractive option for treating neurodevelopmental disorders such as FX. They are prescribed worldwide for the treatment of hypercholesterolemia and coronary heart disease (<xref ref-type="bibr" rid="B13">Istvan, 2003</xref>), and safely used for long-term treatment in children and adults (<xref ref-type="bibr" rid="B24">Ling and Tejada-Simon, 2016</xref>). However, our study suggests that care should be taken when considering which statin should be trialed for the treatment of FX and other disorders of excess Ras. Although the effect of different statins on cholesterol synthesis has been well documented, the differential impact on Ras-ERK1/2 signaling is not well established. We show here that, contrary to lovastatin, simvastatin fails to inhibit the Ras-ERK1/2 pathway in the <italic>Fmr1<sup>-/y</sup></italic> hippocampus, exacerbates the already elevated protein synthesis phenotype, and does not correct the AGS phenotype. These results are significant for considering future studies with lovastatin or simvastatin in FX or other disorders of excess Ras. Indeed, clinical trials using simvastatin for the treatment of NF1 have shown little promise, while trials with lovastatin show an improvement in cognitive deficits (<xref ref-type="bibr" rid="B47">van der Vaart et al., 2013</xref>; <xref ref-type="bibr" rid="B4">Bearden et al., 2016</xref>; <xref ref-type="bibr" rid="B35">Payne et al., 2016</xref>). Although further studies testing a broader dose range of simvastatin on additional <italic>Fmr1<sup>-/y</sup></italic> brain phenotypes will ultimately determine the feasibility of this strategy for FX, our study suggests caution should be used when assuming simvastatin is a suitable substitute for lovastatin.</p>
</sec>
</body>
<back>
<ack>
<p>Acknowledgements: We thank the contributions of all members of the Osterweil lab, with special thanks to Sophie Thomson, Sang Seo, Steph Barnes, and Caoimhe Kirby. We also thank Peter Kind and Mike Cousin for helpful insights and advice.</p>
</ack>
<ref-list content-type="nameDate">
<title>References</title>
<ref id="B1">
<mixed-citation publication-type="book">
<collab>Alabama-Birmingham U, NCI 2009</collab> (<year>2010</year>) <source/>A randomized placebo-controlled study of lovastatin in children with neurofibromatosis type 1 (STARS). <publisher-name>ClinicalTrialsgov</publisher-name> Available at <ext-link ext-link-type="uri" xlink:href="https://clinicaltrials.gov/ct2/show/NCT00853580">https://clinicaltrials.gov/ct2/show/NCT00853580</ext-link>. Accessed on March 12, 2018.
</mixed-citation>
</ref>
<ref id="B2">
<mixed-citation publication-type="journal">
<string-name><surname>Ashley</surname>
<given-names>CT</given-names>
<suffix>Jr</suffix></string-name>, <string-name><surname>Wilkinson</surname>
<given-names>KD</given-names></string-name>, <string-name><surname>Reines</surname>
<given-names>D</given-names></string-name>, <string-name><surname>Warren</surname>
<given-names>ST</given-names></string-name> (<year>1993</year>) <article-title>FMR1 protein: conserved RNP family domains and selective RNA binding</article-title>. <source/>Science
<volume>262</volume>:<fpage>563</fpage>–<lpage>566</lpage>. <pub-id pub-id-type="pmid">7692601</pub-id></mixed-citation>
</ref>
<ref id="B3">
<mixed-citation publication-type="journal">
<string-name><surname>Bear</surname>
<given-names>MF</given-names></string-name>, <string-name><surname>Huber</surname>
<given-names>KM</given-names></string-name>, <string-name><surname>Warren</surname>
<given-names>ST</given-names></string-name> (<year>2004</year>) <article-title>The mGluR theory of fragile X mental retardation</article-title>. <source/>Trends Neurosci
<volume>27</volume>:<fpage>370</fpage>–<lpage>377</lpage>. <pub-id pub-id-type="doi">10.1016/j.tins.2004.04.009</pub-id>
<pub-id pub-id-type="pmid">15219735</pub-id></mixed-citation>
</ref>
<ref id="B4">
<mixed-citation publication-type="journal">
<string-name><surname>Bearden</surname>
<given-names>CE</given-names></string-name>, <string-name><surname>Hellemann</surname>
<given-names>GS</given-names></string-name>, <string-name><surname>Rosser</surname>
<given-names>T</given-names></string-name>, <string-name><surname>Montojo</surname>
<given-names>C</given-names></string-name>, <string-name><surname>Jonas</surname>
<given-names>R</given-names></string-name>, <string-name><surname>Enrique</surname>
<given-names>N</given-names></string-name>, <string-name><surname>Pacheco</surname>
<given-names>L</given-names></string-name>, <string-name><surname>Hussain</surname>
<given-names>SA</given-names></string-name>, <string-name><surname>Wu</surname>
<given-names>JY</given-names></string-name>, <string-name><surname>Ho</surname>
<given-names>JS</given-names></string-name>, <string-name><surname>McGough</surname>
<given-names>JJ</given-names></string-name>, <string-name><surname>Sugar</surname>
<given-names>CA</given-names></string-name>, <string-name><surname>Silva</surname>
<given-names>AJ</given-names></string-name> (<year>2016</year>) <article-title>A randomized placebo-controlled lovastatin trial for neurobehavioral function in neurofibromatosis I</article-title>. <source/>Ann Clin Transl Neurol
<volume>3</volume>:<fpage>266</fpage>–<lpage>279</lpage>. <pub-id pub-id-type="doi">10.1002/acn3.288</pub-id>
<pub-id pub-id-type="pmid">27081657</pub-id></mixed-citation>
</ref>
<ref id="B5">
<mixed-citation publication-type="journal">
<string-name><surname>Berry-Kravis</surname>
<given-names>E</given-names></string-name> (<year>2002</year>) <article-title>Epilepsy in fragile X syndrome</article-title>. <source/>Dev Med Child Neurol
<volume>44</volume>:<fpage>724</fpage>–<lpage>728</lpage>. <pub-id pub-id-type="pmid">12418611</pub-id></mixed-citation>
</ref>
<ref id="B6">
<mixed-citation publication-type="journal">
<string-name><surname>Berry-Kravis</surname>
<given-names>EM</given-names></string-name>, <string-name><surname>Lindemann</surname>
<given-names>L</given-names></string-name>, <string-name><surname>Jonch</surname>
<given-names>AE</given-names></string-name>, <string-name><surname>Apostol</surname>
<given-names>G</given-names></string-name>, <string-name><surname>Bear</surname>
<given-names>MF</given-names></string-name>, <string-name><surname>Carpenter</surname>
<given-names>RL</given-names></string-name>, <string-name><surname>Crawley</surname>
<given-names>JN</given-names></string-name>, <string-name><surname>Curie</surname>
<given-names>A</given-names></string-name>, <string-name><surname>Des Portes</surname>
<given-names>V</given-names></string-name>, <string-name><surname>Hossain</surname>
<given-names>F</given-names></string-name>, <string-name><surname>Gasparini</surname>
<given-names>F</given-names></string-name>, <string-name><surname>Gomez-Mancilla</surname>
<given-names>B</given-names></string-name>, <string-name><surname>Hessl</surname>
<given-names>D</given-names></string-name>, <string-name><surname>Loth</surname>
<given-names>E</given-names></string-name>, <string-name><surname>Scharf</surname>
<given-names>SH</given-names></string-name>, <string-name><surname>Wang</surname>
<given-names>PP</given-names></string-name>, <string-name><surname>Von Raison</surname>
<given-names>F</given-names></string-name>, <string-name><surname>Hagerman</surname>
<given-names>R</given-names></string-name>, <string-name><surname>Spooren</surname>
<given-names>W</given-names></string-name>, <string-name><surname>Jacquemont</surname>
<given-names>S</given-names></string-name> (<year>2017</year>) <article-title>Drug development for neurodevelopmental disorders: lessons learned from fragile X syndrome</article-title>. <source/>Nat Rev Drug Discovery
<volume>17</volume>:<fpage>280</fpage>–<lpage>299</lpage>.
<pub-id pub-id-type="pmid">29217836</pub-id></mixed-citation>
</ref>
<ref id="B7">
<mixed-citation publication-type="journal">
<string-name><surname>Busquets-Garcia</surname>
<given-names>A</given-names></string-name>, <string-name><surname>Gomis-González</surname>
<given-names>M</given-names></string-name>, <string-name><surname>Guegan</surname>
<given-names>T</given-names></string-name>, <string-name><surname>Agustín-Pavón</surname>
<given-names>C</given-names></string-name>, <string-name><surname>Pastor</surname>
<given-names>A</given-names></string-name>, <string-name><surname>Mato</surname>
<given-names>S</given-names></string-name>, <string-name><surname>Pérez-Samartín</surname>
<given-names>A</given-names></string-name>, <string-name><surname>Matute</surname>
<given-names>C</given-names></string-name>, <string-name><surname>de la Torre</surname>
<given-names>R</given-names></string-name>, <string-name><surname>Dierssen</surname>
<given-names>M</given-names></string-name>, <string-name><surname>Maldonado</surname>
<given-names>R</given-names></string-name>, <string-name><surname>Ozaita</surname>
<given-names>A</given-names></string-name> (<year>2013</year>) <article-title>Targeting the endocannabinoid system in the treatment of fragile X syndrome</article-title>. <source/>Nat Med
<volume>19</volume>:<fpage>603</fpage>–<lpage>607</lpage>. <pub-id pub-id-type="doi">10.1038/nm.3127</pub-id><pub-id pub-id-type="pmid">23542787</pub-id></mixed-citation>
</ref>
<ref id="B8">
<mixed-citation publication-type="journal">
<string-name><surname>Çaku</surname>
<given-names>A</given-names></string-name>, <string-name><surname>Pellerin</surname>
<given-names>D</given-names></string-name>, <string-name><surname>Bouvier</surname>
<given-names>P</given-names></string-name>, <string-name><surname>Riou</surname>
<given-names>E</given-names></string-name>, <string-name><surname>Corbin</surname>
<given-names>F</given-names></string-name> (<year>2014</year>) <article-title>Effect of lovastatin on behavior in children and adults with fragile X syndrome: an open-label study</article-title>. <source/>Am J Med Genet A
<volume>164A</volume>:<fpage>2834</fpage>–<lpage>2842</lpage>. <pub-id pub-id-type="doi">10.1002/ajmg.a.36750</pub-id>
<pub-id pub-id-type="pmid">25258112</pub-id></mixed-citation>
</ref>
<ref id="B9">
<mixed-citation publication-type="journal">
<string-name><surname>Darnell</surname>
<given-names>JC</given-names></string-name>, <string-name><surname>Van Driesche</surname>
<given-names>SJ</given-names></string-name>, <string-name><surname>Zhang</surname>
<given-names>C</given-names></string-name>, <string-name><surname>Hung</surname>
<given-names>KY</given-names></string-name>, <string-name><surname>Mele</surname>
<given-names>A</given-names></string-name>, <string-name><surname>Fraser</surname>
<given-names>CE</given-names></string-name>, <string-name><surname>Stone</surname>
<given-names>EF</given-names></string-name>, <string-name><surname>Chen</surname>
<given-names>C</given-names></string-name>, <string-name><surname>Fak</surname>
<given-names>JJ</given-names></string-name>, <string-name><surname>Chi</surname>
<given-names>SW</given-names></string-name>, <string-name><surname>Licatalosi</surname>
<given-names>DD</given-names></string-name>, <string-name><surname>Richter</surname>
<given-names>JD</given-names></string-name>, <string-name><surname>Darnell</surname>
<given-names>RB</given-names></string-name> (<year>2011</year>) <article-title>FMRP stalls ribosomal translocation on mRNAs linked to synaptic function and autism</article-title>. <source/>Cell
<volume>146</volume>:<fpage>247</fpage>–<lpage>261</lpage>. <pub-id pub-id-type="doi">10.1016/j.cell.2011.06.013</pub-id>
<pub-id pub-id-type="pmid">21784246</pub-id></mixed-citation>
</ref>
<ref id="B10">
<mixed-citation publication-type="journal">
<string-name><surname>Dölen</surname>
<given-names>G</given-names></string-name>, <string-name><surname>Osterweil</surname>
<given-names>E</given-names></string-name>, <string-name><surname>Rao</surname>
<given-names>BS</given-names></string-name>, <string-name><surname>Smith</surname>
<given-names>GB</given-names></string-name>, <string-name><surname>Auerbach</surname>
<given-names>BD</given-names></string-name>, <string-name><surname>Chattarji</surname>
<given-names>S</given-names></string-name>, <string-name><surname>Bear</surname>
<given-names>MF</given-names></string-name> (<year>2007</year>) <article-title>Correction of fragile X syndrome in mice</article-title>. <source/>Neuron
<volume>56</volume>:<fpage>955</fpage>–<lpage>962</lpage>. <pub-id pub-id-type="doi">10.1016/j.neuron.2007.12.001</pub-id>
<pub-id pub-id-type="pmid">18093519</pub-id></mixed-citation>
</ref>
<ref id="B11">
<mixed-citation publication-type="journal">
<string-name><surname>Hagerman</surname>
<given-names>RJ</given-names></string-name>, <string-name><surname>Berry-Kravis</surname>
<given-names>E</given-names></string-name>, <string-name><surname>Kaufmann</surname>
<given-names>WE</given-names></string-name>, <string-name><surname>Ono</surname>
<given-names>MY</given-names></string-name>, <string-name><surname>Tartaglia</surname>
<given-names>N</given-names></string-name>, <string-name><surname>Lachiewicz</surname>
<given-names>A</given-names></string-name>, <string-name><surname>Kronk</surname>
<given-names>R</given-names></string-name>, <string-name><surname>Delahunty</surname>
<given-names>C</given-names></string-name>, <string-name><surname>Hessl</surname>
<given-names>D</given-names></string-name>, <string-name><surname>Visootsak</surname>
<given-names>J</given-names></string-name>, <string-name><surname>Picker</surname>
<given-names>J</given-names></string-name>, <string-name><surname>Gane</surname>
<given-names>L</given-names></string-name>, <string-name><surname>Tranfaglia</surname>
<given-names>M</given-names></string-name> (<year>2009</year>) <article-title>Advances in the treatment of fragile X syndrome</article-title>. <source/>Pediatrics
<volume>123</volume>:<fpage>378</fpage>–<lpage>390</lpage>. <pub-id pub-id-type="doi">10.1542/peds.2008-0317</pub-id>
<pub-id pub-id-type="pmid">19117905</pub-id></mixed-citation>
</ref>
<ref id="B12">
<mixed-citation publication-type="journal">
<string-name><surname>Higgins</surname>
<given-names>JW</given-names></string-name>, <string-name><surname>Bao</surname>
<given-names>JQ</given-names></string-name>, <string-name><surname>Ke</surname>
<given-names>AB</given-names></string-name>, <string-name><surname>Manro</surname>
<given-names>JR</given-names></string-name>, <string-name><surname>Fallon</surname>
<given-names>JK</given-names></string-name>, <string-name><surname>Smith</surname>
<given-names>PC</given-names></string-name>, <string-name><surname>Zamek-Gliszczynski</surname>
<given-names>MJ</given-names></string-name> (<year>2014</year>) <article-title>Utility of Oatp1a/1b-knockout and OATP1B1/3-humanized mice in the study of OATP-mediated pharmacokinetics and tissue distribution: case studies with pravastatin, atorvastatin, simvastatin, and carboxydichlorofluorescein</article-title>. <source/>Drug Metab Dispos
<volume>42</volume>:<fpage>182</fpage>–<lpage>192</lpage>. <pub-id pub-id-type="doi">10.1124/dmd.113.054783</pub-id><pub-id pub-id-type="pmid">24194513</pub-id></mixed-citation>
</ref>
<ref id="B13">
<mixed-citation publication-type="journal">
<string-name><surname>Istvan</surname>
<given-names>E</given-names></string-name> (<year>2003</year>) <article-title>Statin inhibition of HMG-CoA reductase: a 3-dimensional view</article-title>. <source/>Atheroscler Suppl
<volume>4</volume>:<fpage>3</fpage>–<lpage>8</lpage>. <pub-id pub-id-type="pmid">12714031</pub-id></mixed-citation>
</ref>
<ref id="B14">
<mixed-citation publication-type="journal">
<string-name><surname>Johnson-Anuna</surname>
<given-names>LN</given-names></string-name>, <string-name><surname>Eckert</surname>
<given-names>GP</given-names></string-name>, <string-name><surname>Keller</surname>
<given-names>JH</given-names></string-name>, <string-name><surname>Igbavboa</surname>
<given-names>U</given-names></string-name>, <string-name><surname>Franke</surname>
<given-names>C</given-names></string-name>, <string-name><surname>Fechner</surname>
<given-names>T</given-names></string-name>, <string-name><surname>Schubert-Zsilavecz</surname>
<given-names>M</given-names></string-name>, <string-name><surname>Karas</surname>
<given-names>M</given-names></string-name>, <string-name><surname>Müller</surname>
<given-names>WE</given-names></string-name>, <string-name><surname>Wood</surname>
<given-names>WG</given-names></string-name> (<year>2005</year>) <article-title>Chronic administration of statins alters multiple gene expression patterns in mouse cerebral cortex</article-title>. <source/>J Pharmacol Exp Ther
<volume>312</volume>:<fpage>786</fpage>–<lpage>793</lpage>. <pub-id pub-id-type="doi">10.1124/jpet.104.075028</pub-id>
<pub-id pub-id-type="pmid">15358814</pub-id></mixed-citation>
</ref>
<ref id="B15">
<mixed-citation publication-type="journal">
<string-name><surname>Johnson-Anuna</surname>
<given-names>LN</given-names></string-name>, <string-name><surname>Eckert</surname>
<given-names>GP</given-names></string-name>, <string-name><surname>Franke</surname>
<given-names>C</given-names></string-name>, <string-name><surname>Igbavboa</surname>
<given-names>U</given-names></string-name>, <string-name><surname>Müller</surname>
<given-names>WE</given-names></string-name>, <string-name><surname>Wood</surname>
<given-names>WG</given-names></string-name> (<year>2007</year>) <article-title>Simvastatin protects neurons from cytotoxicity by up-regulating Bcl-2 mRNA and protein</article-title>. <source/>J Neurochem
<volume>101</volume>:<fpage>77</fpage>–<lpage>86</lpage>. <pub-id pub-id-type="doi">10.1111/j.1471-4159.2006.04375.x</pub-id>
<pub-id pub-id-type="pmid">17241114</pub-id></mixed-citation>
</ref>
<ref id="B16">
<mixed-citation publication-type="journal">
<string-name><surname>Jones</surname>
<given-names>P</given-names></string-name>, <string-name><surname>Kafonek</surname>
<given-names>S</given-names></string-name>, <string-name><surname>Laurora</surname>
<given-names>I</given-names></string-name>, <string-name><surname>Hunninghake</surname>
<given-names>D</given-names></string-name> (<year>1998</year>) <article-title>Comparative dose efficacy study of atorvastatin versus simvastatin, pravastatin, lovastatin, and fluvastatin in patients with hypercholesterolemia (the CURVES study)</article-title>. <source/>Am J Cardiol
<volume>81</volume>:<fpage>582</fpage>–<lpage>587</lpage>. <pub-id pub-id-type="pmid">9514454</pub-id></mixed-citation>
</ref>
<ref id="B17">
<mixed-citation publication-type="journal">
<string-name><surname>King</surname>
<given-names>MK</given-names></string-name>, <string-name><surname>Jope</surname>
<given-names>RS</given-names></string-name> (<year>2013</year>) <article-title>Lithium treatment alleviates impaired cognition in a mouse model of fragile X syndrome</article-title>. <source/>Genes Brain Behav
<volume>12</volume>:<fpage>723</fpage>–<lpage>731</lpage>. <pub-id pub-id-type="pmid">23941202</pub-id></mixed-citation>
</ref>
<ref id="B19">
<mixed-citation publication-type="journal">
<string-name><surname>Krab</surname>
<given-names>LC</given-names></string-name>, <string-name><surname>de Goede-Bolder</surname>
<given-names>A</given-names></string-name>, <string-name><surname>Aarsen</surname>
<given-names>FK</given-names></string-name>, <string-name><surname>Pluijm</surname>
<given-names>SM</given-names></string-name>, <string-name><surname>Bouman</surname>
<given-names>MJ</given-names></string-name>, <string-name><surname>van der Geest</surname>
<given-names>JN</given-names></string-name>, <string-name><surname>Lequin</surname>
<given-names>M</given-names></string-name>, <string-name><surname>Catsman</surname>
<given-names>CE</given-names></string-name>, <string-name><surname>Arts</surname>
<given-names>WF</given-names></string-name>, <string-name><surname>Kushner</surname>
<given-names>SA</given-names></string-name>, <string-name><surname>Silva</surname>
<given-names>AJ</given-names></string-name>, <string-name><surname>de Zeeuw</surname>
<given-names>CI</given-names></string-name>, <string-name><surname>Moll</surname>
<given-names>HA</given-names></string-name>, <string-name><surname>Elgersma</surname>
<given-names>Y</given-names></string-name> (<year>2008</year>) <article-title>Effect of simvastatin on cognitive functioning in children with neurofibromatosis type 1: a randomized controlled trial</article-title>. <source/>JAMA
<volume>300</volume>:<fpage>287</fpage>–<lpage>294</lpage>. <pub-id pub-id-type="doi">10.1001/jama.300.3.287</pub-id>
<pub-id pub-id-type="pmid">18632543</pub-id></mixed-citation>
</ref>
<ref id="B20">
<mixed-citation publication-type="journal">
<string-name><surname>Li</surname>
<given-names>L</given-names></string-name>, <string-name><surname>Cao</surname>
<given-names>D</given-names></string-name>, <string-name><surname>Kim</surname>
<given-names>H</given-names></string-name>, <string-name><surname>Lester</surname>
<given-names>R</given-names></string-name>, <string-name><surname>Fukuchi</surname>
<given-names>K</given-names></string-name> (<year>2006</year>) <article-title>Simvastatin enhances learning and memory independent of amyloid load in mice</article-title>. <source/>Ann Neurol
<volume>60</volume>:<fpage>729</fpage>–<lpage>739</lpage>. <pub-id pub-id-type="doi">10.1002/ana.21053</pub-id>
<pub-id pub-id-type="pmid">17192930</pub-id></mixed-citation>
</ref>
<ref id="B21">
<mixed-citation publication-type="journal">
<string-name><surname>Li</surname>
<given-names>W</given-names></string-name>, <string-name><surname>Cui</surname>
<given-names>Y</given-names></string-name>, <string-name><surname>Kushner</surname>
<given-names>SA</given-names></string-name>, <string-name><surname>Brown</surname>
<given-names>RA</given-names></string-name>, <string-name><surname>Jentsch</surname>
<given-names>JD</given-names></string-name>, <string-name><surname>Frankland</surname>
<given-names>PW</given-names></string-name>, <string-name><surname>Cannon</surname>
<given-names>TD</given-names></string-name>, <string-name><surname>Silva</surname>
<given-names>AJ</given-names></string-name> (<year>2005</year>) <article-title>The HMG-CoA reductase inhibitor lovastatin reverses the learning and attention deficits in a mouse model of neurofibromatosis type 1</article-title>. <source/>Curr Biol
<volume>15</volume>:<fpage>1961</fpage>–<lpage>1967</lpage>. <pub-id pub-id-type="doi">10.1016/j.cub.2005.09.043</pub-id><pub-id pub-id-type="pmid">16271875</pub-id></mixed-citation>
</ref>
<ref id="B22">
<mixed-citation publication-type="journal">
<string-name><surname>Liao</surname>
<given-names>JK</given-names></string-name>, <string-name><surname>Laufs</surname>
<given-names>U</given-names></string-name> (<year>2005</year>) <article-title>Pleiotropic effects of statins</article-title>. <source/>Annu Rev Pharmacol Toxicol
<volume>45</volume>:<fpage>89</fpage>–<lpage>118</lpage>. <pub-id pub-id-type="doi">10.1146/annurev.pharmtox.45.120403.095748</pub-id>
<pub-id pub-id-type="pmid">15822172</pub-id></mixed-citation>
</ref>
<ref id="B23">
<mixed-citation publication-type="journal">
<string-name><surname>Lim</surname>
<given-names>JH</given-names></string-name>, <string-name><surname>Lee</surname>
<given-names>JC</given-names></string-name>, <string-name><surname>Lee</surname>
<given-names>YH</given-names></string-name>, <string-name><surname>Choi</surname>
<given-names>IY</given-names></string-name>, <string-name><surname>Oh</surname>
<given-names>YK</given-names></string-name>, <string-name><surname>Kim</surname>
<given-names>HS</given-names></string-name>, <string-name><surname>Park</surname>
<given-names>JS</given-names></string-name>, <string-name><surname>Kim</surname>
<given-names>WK</given-names></string-name> (<year>2006</year>) <article-title>Simvastatin prevents oxygen and glucose deprivation/reoxygenation-induced death of cortical neurons by reducing the production and toxicity of 4-hydroxy-2E-nonenal</article-title>. <source/>J Neurochem
<volume>97</volume>:<fpage>140</fpage>–<lpage>150</lpage>. <pub-id pub-id-type="doi">10.1111/j.1471-4159.2006.03715.x</pub-id>
<pub-id pub-id-type="pmid">16515553</pub-id></mixed-citation>
</ref>
<ref id="B24">
<mixed-citation publication-type="journal">
<string-name><surname>Ling</surname>
<given-names>Q</given-names></string-name>, <string-name><surname>Tejada-Simon</surname>
<given-names>MV</given-names></string-name> (<year>2016</year>) <article-title>Statins and the brain: new perspective for old drugs</article-title>. <source/>Prog Neuropsychopharmacol Biol Psychiatry
<volume>66</volume>:<fpage>80</fpage>–<lpage>86</lpage>. <pub-id pub-id-type="doi">10.1016/j.pnpbp.2015.11.013</pub-id>
<pub-id pub-id-type="pmid">26655447</pub-id></mixed-citation>
</ref>
<ref id="B25">
<mixed-citation publication-type="journal">
<string-name><surname>Lozano</surname>
<given-names>R</given-names></string-name>, <string-name><surname>Rosero</surname>
<given-names>CA</given-names></string-name>, <string-name><surname>Hagerman</surname>
<given-names>RJ</given-names></string-name> (<year>2014</year>) <article-title>Fragile X spectrum disorders</article-title>. <source/>Intractable Rare Dis Res
<volume>3</volume>:<fpage>134</fpage>–<lpage>146</lpage>. <pub-id pub-id-type="doi">10.5582/irdr.2014.01022</pub-id>
<pub-id pub-id-type="pmid">25606363</pub-id></mixed-citation>
</ref>
<ref id="B26">
<mixed-citation publication-type="journal">
<string-name><surname>Mans</surname>
<given-names>RA</given-names></string-name>, <string-name><surname>Chowdhury</surname>
<given-names>N</given-names></string-name>, <string-name><surname>Cao</surname>
<given-names>D</given-names></string-name>, <string-name><surname>McMahon</surname>
<given-names>LL</given-names></string-name>, <string-name><surname>Li</surname>
<given-names>L</given-names></string-name> (<year>2010</year>) <article-title>Simvastatin enhances hippocampal long-term potentiation in C57BL/6 mice</article-title>. <source/>Neuroscience
<volume>166</volume>:<fpage>435</fpage>–<lpage>444</lpage>. <pub-id pub-id-type="doi">10.1016/j.neuroscience.2009.12.062</pub-id>
<pub-id pub-id-type="pmid">20040368</pub-id></mixed-citation>
</ref>
<ref id="B27">
<mixed-citation publication-type="journal">
<string-name><surname>Mendola</surname>
<given-names>CE</given-names></string-name>, <string-name><surname>Backer</surname>
<given-names>JM</given-names></string-name> (<year>1990</year>) <article-title>Lovastatin blocks N-ras oncogene-induced neuronal differentiation</article-title>. <source/>Cell Growth Differ
<volume>1</volume>:<fpage>499</fpage>–<lpage>502</lpage>. <pub-id pub-id-type="pmid">2278880</pub-id></mixed-citation>
</ref>
<ref id="B28">
<mixed-citation publication-type="journal">
<string-name><surname>Michalon</surname>
<given-names>A</given-names></string-name>, <string-name><surname>Sidorov</surname>
<given-names>M</given-names></string-name>, <string-name><surname>Ballard</surname>
<given-names>TM</given-names></string-name>, <string-name><surname>Ozmen</surname>
<given-names>L</given-names></string-name>, <string-name><surname>Spooren</surname>
<given-names>W</given-names></string-name>, <string-name><surname>Wettstein</surname>
<given-names>JG</given-names></string-name>, <string-name><surname>Jaeschke</surname>
<given-names>G</given-names></string-name>, <string-name><surname>Bear</surname>
<given-names>MF</given-names></string-name>, <string-name><surname>Lindemann</surname>
<given-names>L</given-names></string-name> (<year>2012</year>) <article-title>Chronic pharmacological mGlu5 inhibition corrects fragile X in adult mice</article-title>. <source/>Neuron
<volume>74</volume>:<fpage>49</fpage>–<lpage>56</lpage>. <pub-id pub-id-type="doi">10.1016/j.neuron.2012.03.009</pub-id>
<pub-id pub-id-type="pmid">22500629</pub-id></mixed-citation>
</ref>
<ref id="B29">
<mixed-citation publication-type="journal">
<string-name><surname>Musumeci</surname>
<given-names>SA</given-names></string-name>, <string-name><surname>Bosco</surname>
<given-names>P</given-names></string-name>, <string-name><surname>Calabrese</surname>
<given-names>G</given-names></string-name>, <string-name><surname>Bakker</surname>
<given-names>C</given-names></string-name>, <string-name><surname>De Sarro</surname>
<given-names>GB</given-names></string-name>, <string-name><surname>Elia</surname>
<given-names>M</given-names></string-name>, <string-name><surname>Ferri</surname>
<given-names>R</given-names></string-name>, <string-name><surname>Oostra</surname>
<given-names>BA</given-names></string-name> (<year>2000</year>) <article-title>Audiogenic seizures susceptibility in transgenic mice with fragile X syndrome</article-title>. <source/>Epilepsia
<volume>41</volume>:<fpage>19</fpage>–<lpage>23</lpage>. <pub-id pub-id-type="doi">10.1111/j.1528-1157.2000.tb01499.x</pub-id><pub-id pub-id-type="pmid">10643918</pub-id></mixed-citation>
</ref>
<ref id="B30">
<mixed-citation publication-type="journal">
<string-name><surname>Nair</surname>
<given-names>AB</given-names></string-name>, <string-name><surname>Jacob</surname>
<given-names>S</given-names></string-name> (<year>2016</year>) <article-title>A simple practice guide for dose conversion between animals and human</article-title>. <source/>J Basic Clin Pharm
<volume>7</volume>:<fpage>27</fpage>–<lpage>31</lpage>. <pub-id pub-id-type="doi">10.4103/0976-0105.177703</pub-id><pub-id pub-id-type="pmid">27057123</pub-id></mixed-citation>
</ref>
<ref id="B31">
<mixed-citation publication-type="journal">
<string-name><surname>Neuvonen</surname>
<given-names>PJ</given-names></string-name>, <string-name><surname>Backman</surname>
<given-names>JT</given-names></string-name>, <string-name><surname>Niemi</surname>
<given-names>M</given-names></string-name> (<year>2008</year>) <article-title>Pharmacokinetic comparison of the potential over-the-counter statins simvastatin, lovastatin, fluvastatin and pravastatin</article-title>. <source/>Clin Pharmacokinet
<volume>47</volume>:<fpage>463</fpage>–<lpage>474</lpage>. <pub-id pub-id-type="doi">10.2165/00003088-200847070-00003</pub-id>
<pub-id pub-id-type="pmid">18563955</pub-id></mixed-citation>
</ref>
<ref id="B32">
<mixed-citation publication-type="journal">
<string-name><surname>Nürenberg</surname>
<given-names>G</given-names></string-name>, <string-name><surname>Volmer</surname>
<given-names>DA</given-names></string-name> (<year>2012</year>) <article-title>The analytical determination of isoprenoid intermediates from the mevalonate pathway</article-title>. <source/>Anal Bioanal Chem
<volume>402</volume>:<fpage>671</fpage>–<lpage>685</lpage>. <pub-id pub-id-type="doi">10.1007/s00216-011-5262-2</pub-id>
<pub-id pub-id-type="pmid">21789486</pub-id></mixed-citation>
</ref>
<ref id="B33">
<mixed-citation publication-type="journal">
<string-name><surname>Osterweil</surname>
<given-names>EK</given-names></string-name>, <string-name><surname>Krueger</surname>
<given-names>DD</given-names></string-name>, <string-name><surname>Reinhold</surname>
<given-names>K</given-names></string-name>, <string-name><surname>Bear</surname>
<given-names>MF</given-names></string-name> (<year>2010</year>) <article-title>Hypersensitivity to mGluR5 and ERK1/2 leads to excessive protein synthesis in the hippocampus of a mouse model of fragile X syndrome</article-title>. <source/>J Neurosci
<volume>30</volume>:<fpage>15616</fpage>–<lpage>15627</lpage>. <pub-id pub-id-type="doi">10.1523/JNEUROSCI.3888-10.2010</pub-id>
<pub-id pub-id-type="pmid">21084617</pub-id></mixed-citation>
</ref>
<ref id="B34">
<mixed-citation publication-type="journal">
<string-name><surname>Osterweil</surname>
<given-names>EK</given-names></string-name>, <string-name><surname>Chuang</surname>
<given-names>SC</given-names></string-name>, <string-name><surname>Chubykin</surname>
<given-names>AA</given-names></string-name>, <string-name><surname>Sidorov</surname>
<given-names>M</given-names></string-name>, <string-name><surname>Bianchi</surname>
<given-names>R</given-names></string-name>, <string-name><surname>Wong</surname>
<given-names>RK</given-names></string-name>, <string-name><surname>Bear</surname>
<given-names>MF</given-names></string-name> (<year>2013</year>) <article-title>Lovastatin corrects excess protein synthesis and prevents epileptogenesis in a mouse model of fragile X syndrome</article-title>. <source/>Neuron
<volume>77</volume>:<fpage>243</fpage>–<lpage>250</lpage>. <pub-id pub-id-type="doi">10.1016/j.neuron.2012.01.034</pub-id><pub-id pub-id-type="pmid">23352161</pub-id></mixed-citation>
</ref>
<ref id="B35">
<mixed-citation publication-type="journal">
<string-name><surname>Payne</surname>
<given-names>JM</given-names></string-name>, <string-name><surname>Barton</surname>
<given-names>B</given-names></string-name>, <string-name><surname>Ullrich</surname>
<given-names>NJ</given-names></string-name>, <string-name><surname>Cantor</surname>
<given-names>A</given-names></string-name>, <string-name><surname>Hearps</surname>
<given-names>SJ</given-names></string-name>, <string-name><surname>Cutter</surname>
<given-names>G</given-names></string-name>, <string-name><surname>Rosser</surname>
<given-names>T</given-names></string-name>, <string-name><surname>Walsh</surname>
<given-names>KS</given-names></string-name>, <string-name><surname>Gioia</surname>
<given-names>GA</given-names></string-name>, <string-name><surname>Wolters</surname>
<given-names>PL</given-names></string-name>, <string-name><surname>Tonsgard</surname>
<given-names>J</given-names></string-name>, <string-name><surname>Schorry</surname>
<given-names>E</given-names></string-name>, <string-name><surname>Viskochil</surname>
<given-names>D</given-names></string-name>, <string-name><surname>Klesse</surname>
<given-names>L</given-names></string-name>, <string-name><surname>Fisher</surname>
<given-names>M</given-names></string-name>, <string-name><surname>Gutmann</surname>
<given-names>DH</given-names></string-name>, <string-name><surname>Silva</surname>
<given-names>AJ</given-names></string-name>, <string-name><surname>Hunter</surname>
<given-names>SJ</given-names></string-name>, <string-name><surname>Rey-Casserly</surname>
<given-names>C</given-names></string-name>, <string-name><surname>Cantor</surname>
<given-names>NL</given-names></string-name>, <etal>et al</etal>. (<year>2016</year>) <article-title>Randomized placebo-controlled study of lovastatin in children with neurofibromatosis type 1</article-title>. <source/>Neurology
<volume>87</volume>:<fpage>2575</fpage>–<lpage>2584</lpage>. <pub-id pub-id-type="doi">10.1212/WNL.0000000000003435</pub-id>
<pub-id pub-id-type="pmid">27956565</pub-id></mixed-citation>
</ref>
<ref id="B36">
<mixed-citation publication-type="journal">
<string-name><surname>Pellerin</surname>
<given-names>D</given-names></string-name>, <string-name><surname>Caku</surname>
<given-names>A</given-names></string-name>, <string-name><surname>Fradet</surname>
<given-names>M</given-names></string-name>, <string-name><surname>Bouvier</surname>
<given-names>P</given-names></string-name>, <string-name><surname>Dube</surname>
<given-names>J</given-names></string-name>, <string-name><surname>Corbin</surname>
<given-names>F</given-names></string-name> (<year>2016</year>) <article-title>Lovastatin corrects ERK pathway hyperactivation in fragile X syndrome: potential of platelet's signaling cascades as new outcome measures in clinical trials</article-title>. <source/>Biomarkers
<volume>21</volume>:<fpage>497</fpage>–<lpage>508</lpage>. <pub-id pub-id-type="pmid">27058300</pub-id></mixed-citation>
</ref>
<ref id="B38">
<mixed-citation publication-type="journal">
<string-name><surname>Qin</surname>
<given-names>M</given-names></string-name>, <string-name><surname>Kang</surname>
<given-names>J</given-names></string-name>, <string-name><surname>Burlin</surname>
<given-names>TV</given-names></string-name>, <string-name><surname>Jiang</surname>
<given-names>C</given-names></string-name>, <string-name><surname>Smith</surname>
<given-names>CB</given-names></string-name> (<year>2005</year>) <article-title>Postadolescent changes in regional cerebral protein synthesis: an in vivo study in the FMR1 null mouse</article-title>. <source/>J Neurosci
<volume>25</volume>:<fpage>5087</fpage>–<lpage>5095</lpage>. <pub-id pub-id-type="doi">10.1523/JNEUROSCI.0093-05.2005</pub-id><pub-id pub-id-type="pmid">15901791</pub-id></mixed-citation>
</ref>
<ref id="B39">
<mixed-citation publication-type="journal">
<string-name><surname>Ramirez</surname>
<given-names>C</given-names></string-name>, <string-name><surname>Tercero</surname>
<given-names>I</given-names></string-name>, <string-name><surname>Pineda</surname>
<given-names>A</given-names></string-name>, <string-name><surname>Burgos</surname>
<given-names>JS</given-names></string-name> (<year>2011</year>) <article-title>Simvastatin is the statin that most efficiently protects against kainate-induced excitotoxicity and memory impairment</article-title>. <source/>J Alzheimers Dis
<volume>24</volume>:<fpage>161</fpage>–<lpage>174</lpage>. <pub-id pub-id-type="doi">10.3233/JAD-2010-101653</pub-id>
<pub-id pub-id-type="pmid">21224519</pub-id></mixed-citation>
</ref>
<ref id="B40">
<mixed-citation publication-type="journal">
<string-name><surname>Schachter</surname>
<given-names>M</given-names></string-name> (<year>2005</year>) <article-title>Chemical, pharmacokinetic and pharmacodynamic properties of statins: an update</article-title>. <source/>Fundam Clin Pharmacol
<volume>19</volume>:<fpage>117</fpage>–<lpage>125</lpage>. <pub-id pub-id-type="doi">10.1111/j.1472-8206.2004.00299.x</pub-id>
<pub-id pub-id-type="pmid">15660968</pub-id></mixed-citation>
</ref>
<ref id="B41">
<mixed-citation publication-type="journal">
<string-name><surname>Schaefer</surname>
<given-names>EJ</given-names></string-name>, <string-name><surname>McNamara</surname>
<given-names>JR</given-names></string-name>, <string-name><surname>Tayler</surname>
<given-names>T</given-names></string-name>, <string-name><surname>Daly</surname>
<given-names>JA</given-names></string-name>, <string-name><surname>Gleason</surname>
<given-names>JL</given-names></string-name>, <string-name><surname>Seman</surname>
<given-names>LJ</given-names></string-name>, <string-name><surname>Ferrari</surname>
<given-names>A</given-names></string-name>, <string-name><surname>Rubenstein</surname>
<given-names>JJ</given-names></string-name> (<year>2004</year>) <article-title>Comparisons of effects of statins (atorvastatin, fluvastatin, lovastatin, pravastatin, and simvastatin) on fasting and postprandial lipoproteins in patients with coronary heart disease versus control subjects</article-title>. <source/>Am J Cardiol
<volume>93</volume>:<fpage>31</fpage>–<lpage>39</lpage>. <pub-id pub-id-type="pmid">14697462</pub-id></mixed-citation>
</ref>
<ref id="B42">
<mixed-citation publication-type="journal">
<string-name><surname>Schafer</surname>
<given-names>WR</given-names></string-name>, <string-name><surname>Kim</surname>
<given-names>R</given-names></string-name>, <string-name><surname>Sterne</surname>
<given-names>R</given-names></string-name>, <string-name><surname>Thorner</surname>
<given-names>J</given-names></string-name>, <string-name><surname>Kim</surname>
<given-names>SH</given-names></string-name>, <string-name><surname>Rine</surname>
<given-names>J</given-names></string-name> (<year>1989</year>) <article-title>Genetic and pharmacological suppression of oncogenic mutations in ras genes of yeast and humans</article-title>. <source/>Science
<volume>245</volume>:<fpage>379</fpage>–<lpage>385</lpage>. <pub-id pub-id-type="pmid">2569235</pub-id></mixed-citation>
</ref>
<ref id="B43">
<mixed-citation publication-type="journal">
<string-name><surname>Sharma</surname>
<given-names>A</given-names></string-name>, <string-name><surname>Hoeffer</surname>
<given-names>CA</given-names></string-name>, <string-name><surname>Takayasu</surname>
<given-names>Y</given-names></string-name>, <string-name><surname>Miyawaki</surname>
<given-names>T</given-names></string-name>, <string-name><surname>McBride</surname>
<given-names>SM</given-names></string-name>, <string-name><surname>Klann</surname>
<given-names>E</given-names></string-name>, <string-name><surname>Zukin</surname>
<given-names>RS</given-names></string-name> (<year>2010</year>) <article-title>Dysregulation of mTOR signaling in fragile X syndrome</article-title>. <source/>J Neurosci
<volume>30</volume>:<fpage>694</fpage>–<lpage>702</lpage>. <pub-id pub-id-type="doi">10.1523/JNEUROSCI.3696-09.2010</pub-id>
<pub-id pub-id-type="pmid">20071534</pub-id></mixed-citation>
</ref>
<ref id="B44">
<mixed-citation publication-type="book">
<string-name><surname>Stoppel</surname>
<given-names>LJ</given-names></string-name>, <string-name><surname>Osterweil</surname>
<given-names>EK</given-names></string-name>, <string-name><surname>Bear</surname>
<given-names>MF</given-names></string-name> (<year>2017a</year>) <chapter-title>The mGluR theory from mice to men</chapter-title> In: <source/>Fragile X syndrome: from genetics to targeted treatment (<person-group person-group-type="editor"><name name-style="western"><surname>Willemsen</surname><given-names>R</given-names></name>, <name name-style="western"><surname>Kooy</surname><given-names>F</given-names></name></person-group>, eds). <publisher-loc>London</publisher-loc>: <publisher-name>Elsevier</publisher-name>. </mixed-citation>
</ref>
<ref id="B45">
<mixed-citation publication-type="journal">
<string-name><surname>Stoppel</surname>
<given-names>LJ</given-names></string-name>, <string-name><surname>Kazdoba</surname>
<given-names>TM</given-names></string-name>, <string-name><surname>Schaffler</surname>
<given-names>MD</given-names></string-name>, <string-name><surname>Preza</surname>
<given-names>AR</given-names></string-name>, <string-name><surname>Heynen</surname>
<given-names>A</given-names></string-name>, <string-name><surname>Crawley</surname>
<given-names>JN</given-names></string-name>, <string-name><surname>Bear</surname>
<given-names>MF</given-names></string-name> (<year>2017b</year>) <article-title>R-Baclofen reverses cognitive deficits and improves social interactions in two lines of 16p11.2 deletion mice</article-title>. <source/>Neuropsychopharmacology
<volume>43</volume>:<fpage>513</fpage>–<lpage>524</lpage>. <pub-id pub-id-type="pmid">28984295</pub-id></mixed-citation>
</ref>
<ref id="B46">
<mixed-citation publication-type="journal">
<string-name><surname>Tsuji</surname>
<given-names>A</given-names></string-name>, <string-name><surname>Saheki</surname>
<given-names>A</given-names></string-name>, <string-name><surname>Tamai</surname>
<given-names>I</given-names></string-name>, <string-name><surname>Terasaki</surname>
<given-names>T</given-names></string-name> (<year>1993</year>) <article-title>Transport mechanism of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors at the blood-brain barrier</article-title>. <source/>J Pharmacol Exp Ther
<volume>267</volume>:<fpage>1085</fpage>–<lpage>1090</lpage>. <pub-id pub-id-type="pmid">8263769</pub-id></mixed-citation>
</ref>
<ref id="B47">
<mixed-citation publication-type="journal">
<string-name><surname>van der Vaart</surname>
<given-names>T</given-names></string-name>, <string-name><surname>Plasschaert</surname>
<given-names>E</given-names></string-name>, <string-name><surname>Rietman</surname>
<given-names>AB</given-names></string-name>, <string-name><surname>Renard</surname>
<given-names>M</given-names></string-name>, <string-name><surname>Oostenbrink</surname>
<given-names>R</given-names></string-name>, <string-name><surname>Vogels</surname>
<given-names>A</given-names></string-name>, <string-name><surname>de Wit</surname>
<given-names>MC</given-names></string-name>, <string-name><surname>Descheemaeker</surname>
<given-names>MJ</given-names></string-name>, <string-name><surname>Vergouwe</surname>
<given-names>Y</given-names></string-name>, <string-name><surname>Catsman-Berrevoets</surname>
<given-names>CE</given-names></string-name>, <string-name><surname>Legius</surname>
<given-names>E</given-names></string-name>, <string-name><surname>Elgersma</surname>
<given-names>Y</given-names></string-name>, <string-name><surname>Moll</surname>
<given-names>HA</given-names></string-name> (<year>2013</year>) <article-title>Simvastatin for cognitive deficits and behavioural problems in patients with neurofibromatosis type 1 (NF1-SIMCODA): a randomised, placebo-controlled trial</article-title>. <source/>Lancet Neurol
<volume>12</volume>:<fpage>1076</fpage>–<lpage>1083</lpage>. <pub-id pub-id-type="doi">10.1016/S1474-4422(13)70227-8</pub-id>
<pub-id pub-id-type="pmid">24090588</pub-id></mixed-citation>
</ref>
<ref id="B48">
<mixed-citation publication-type="journal">
<string-name><surname>van de Steeg</surname>
<given-names>E</given-names></string-name>, <string-name><surname>Kleemann</surname>
<given-names>R</given-names></string-name>, <string-name><surname>Jansen</surname>
<given-names>HT</given-names></string-name>, <string-name><surname>van Duyvenvoorde</surname>
<given-names>W</given-names></string-name>, <string-name><surname>Offerman</surname>
<given-names>EH</given-names></string-name>, <string-name><surname>Wortelboer</surname>
<given-names>HM</given-names></string-name>, <string-name><surname>Degroot</surname>
<given-names>J</given-names></string-name> (<year>2013</year>) <article-title>Combined analysis of pharmacokinetic and efficacy data of preclinical studies with statins markedly improves translation of drug efficacy to human trials</article-title>. <source/>J Pharmacol Exp Ther
<volume>347</volume>:<fpage>635</fpage>–<lpage>644</lpage>. <pub-id pub-id-type="doi">10.1124/jpet.113.208595</pub-id>
<pub-id pub-id-type="pmid">24049060</pub-id></mixed-citation>
</ref>
<ref id="B49">
<mixed-citation publication-type="journal">
<string-name><surname>Wang</surname>
<given-names>X</given-names></string-name>, <string-name><surname>Snape</surname>
<given-names>M</given-names></string-name>, <string-name><surname>Klann</surname>
<given-names>E</given-names></string-name>, <string-name><surname>Stone</surname>
<given-names>JG</given-names></string-name>, <string-name><surname>Singh</surname>
<given-names>A</given-names></string-name>, <string-name><surname>Petersen</surname>
<given-names>RB</given-names></string-name>, <string-name><surname>Castellani</surname>
<given-names>RJ</given-names></string-name>, <string-name><surname>Casadesus</surname>
<given-names>G</given-names></string-name>, <string-name><surname>Smith</surname>
<given-names>MA</given-names></string-name>, <string-name><surname>Zhu</surname>
<given-names>X</given-names></string-name> (<year>2012</year>) <article-title>Activation of the extracellular signal-regulated kinase pathway contributes to the behavioral deficit of fragile x-syndrome</article-title>. <source/>J Neurochem
<volume>121</volume>:<fpage>672</fpage>–<lpage>679</lpage>. <pub-id pub-id-type="doi">10.1111/j.1471-4159.2012.07722.x</pub-id>
<pub-id pub-id-type="pmid">22393900</pub-id></mixed-citation>
</ref>
<ref id="B50">
<mixed-citation publication-type="journal">
<string-name><surname>Xie</surname>
<given-names>C</given-names></string-name>, <string-name><surname>Sun</surname>
<given-names>J</given-names></string-name>, <string-name><surname>Qiao</surname>
<given-names>W</given-names></string-name>, <string-name><surname>Lu</surname>
<given-names>D</given-names></string-name>, <string-name><surname>Wei</surname>
<given-names>L</given-names></string-name>, <string-name><surname>Na</surname>
<given-names>M</given-names></string-name>, <string-name><surname>Song</surname>
<given-names>Y</given-names></string-name>, <string-name><surname>Hou</surname>
<given-names>X</given-names></string-name>, <string-name><surname>Lin</surname>
<given-names>Z</given-names></string-name> (<year>2011</year>) <article-title>Administration of simvastatin after kainic acid-induced status epilepticus restrains chronic temporal lobe epilepsy</article-title>. <source/>PLoS One
<volume>6</volume>:<fpage>e24966</fpage>. <pub-id pub-id-type="doi">10.1371/journal.pone.0024966</pub-id>
<pub-id pub-id-type="pmid">21949812</pub-id></mixed-citation>
</ref>
<ref id="B51">
<mixed-citation publication-type="journal">
<string-name><surname>Xu</surname>
<given-names>D</given-names></string-name>, <string-name><surname>Li</surname>
<given-names>F</given-names></string-name>, <string-name><surname>Zhang</surname>
<given-names>M</given-names></string-name>, <string-name><surname>Zhang</surname>
<given-names>J</given-names></string-name>, <string-name><surname>Liu</surname>
<given-names>C</given-names></string-name>, <string-name><surname>Hu</surname>
<given-names>MY</given-names></string-name>, <string-name><surname>Zhong</surname>
<given-names>ZY</given-names></string-name>, <string-name><surname>Jia</surname>
<given-names>LL</given-names></string-name>, <string-name><surname>Wang</surname>
<given-names>DW</given-names></string-name>, <string-name><surname>Wu</surname>
<given-names>J</given-names></string-name>, <string-name><surname>Liu</surname>
<given-names>L</given-names></string-name>, <string-name><surname>Liu</surname>
<given-names>XD</given-names></string-name> (<year>2014</year>) <article-title>Decreased exposure of simvastatin and simvastatin acid in a rat model of type 2 diabetes</article-title>. <source/>Acta Pharmacol Sin
<volume>35</volume>:<fpage>1215</fpage>–<lpage>1225</lpage>. <pub-id pub-id-type="doi">10.1038/aps.2014.39</pub-id>
<pub-id pub-id-type="pmid">25152023</pub-id></mixed-citation>
</ref>
<ref id="B52">
<mixed-citation publication-type="journal">
<string-name><surname>Yan</surname>
<given-names>QJ</given-names></string-name>, <string-name><surname>Asafo-Adjei</surname>
<given-names>PK</given-names></string-name>, <string-name><surname>Arnold</surname>
<given-names>HM</given-names></string-name>, <string-name><surname>Brown</surname>
<given-names>RE</given-names></string-name>, <string-name><surname>Bauchwitz</surname>
<given-names>RP</given-names></string-name> (<year>2004</year>) <article-title>A phenotypic and molecular characterization of the fmr1-tm1Cgr fragile X mouse</article-title>. <source/>Genes Brain Behav
<volume>3</volume>:<fpage>337</fpage>–<lpage>359</lpage>. <pub-id pub-id-type="doi">10.1111/j.1601-183X.2004.00087.x</pub-id>
<pub-id pub-id-type="pmid">15544577</pub-id></mixed-citation>
</ref>
<ref id="B53">
<mixed-citation publication-type="journal">
<string-name><surname>Yan</surname>
<given-names>QJ</given-names></string-name>, <string-name><surname>Rammal</surname>
<given-names>M</given-names></string-name>, <string-name><surname>Tranfaglia</surname>
<given-names>M</given-names></string-name>, <string-name><surname>Bauchwitz</surname>
<given-names>RP</given-names></string-name> (<year>2005</year>) <article-title>Suppression of two major fragile X syndrome mouse model phenotypes by the mGluR5 antagonist MPEP</article-title>. <source/>Neuropharmacology
<volume>49</volume>:<fpage>1053</fpage>–<lpage>1066</lpage>. <pub-id pub-id-type="doi">10.1016/j.neuropharm.2005.06.004</pub-id>
<pub-id pub-id-type="pmid">16054174</pub-id></mixed-citation>
</ref>
</ref-list>
<sec id="s6" sec-type="synthesis-author-response">
<title>Synthesis</title>
<boxed-text orientation="portrait" position="float">
<p>Reviewing Editor: Quentin Pittman, University of Calgary</p>
<p>Decisions are customarily a result of the Reviewing Editor and the peer reviewers coming together and discussing their recommendations until a consensus is reached. When revisions are invited, a fact-based synthesis statement explaining their decision and outlining what is needed to prepare a revision will be listed below. The following reviewer(s) agreed to reveal their identity: Kimberly Huber.</p>
</boxed-text>
<p>In this manuscript authors describe the effects of two statins, lovastatin and simvastatin, in well-described phenotypes of the Fmr1 knockout mouse, a model for fragile X syndrome. </p>
<p>The study finds that simvastatin does not reproduce the effects observed for lovastatin. The effects of lovastatin in the fragile X syndrome mouse model were previously published, and they are mainly reproduced in the present manuscript. Comparatively, simvastatin exposure, under similar experimental conditions than lovastatin, does not produce the same effects, although both drugs are HMG-CoA reductase inhibitors. </p>
<p>The reviewers agree that the findings are important for translational medicine. However, there was some disappointment that the authors did not take advantage of their data to explore alternative mechanisms, since their new data with simvastatin could indicate that lovastatin effects are independent of HMG-CoA reductase inhibition. While eNeuro does not demand elucidation of a mechanism for publication, if the authors have any evidence with respect to this matter they are encouraged to include it in a revision. </p>
<p>Suggestions for revision:</p>
<p>1. Regarding the main text, this is well written but the results section of the manuscript at times serves as an extended section of the introduction, the methods and the discussion sections (first half of page 9 would better fit in the introduction, where mTORC1 pathway is not mentioned; page 12, lines 1-11 would better fit in the methods section; page 11 and other parts of the results section would better fit in the discussion section). The results section should concisely describe the experimental data, and the rest of information should be redistributed. </p>
<p>2. Regarding the experimental data, Figure 1C does not show the phenotype between WT and Fmr1 KO mice, revealing some inconsistencies with the results previously published and those results shown in Figure 1 (B and D). Similarly, in the present experiments the enhanced ERK phosphorylation in basal conditions (Fmr1KO vs WT, in zero concentration of the drugs), previously published by other authors describing the effect of lovastatin, is not observed (Figure 2, B and C), raising questions about the performance of the assay. </p>
<p>3. Other minor drawback is the representative image chosen in Figure 1D. In the representative image for 35S detection, the WT 0 condition and WT 0.5 condition do not seem to reflect the averaged differences observed in the bars plot when comparing the darkest gray column and the lightest gray column. </p>
<p>4. Please detail in the methods how the protein synthesis and _pERK values are normalized. Are all values normalized to WT veh or to vehicle within the same genotype? </p>
<p>5. From the representative western blots in Fig. 2, the appropriate inclusion of a line between the WT and the KO indicates that each lane is cut or separated from adjacent lanes, suggesting that the authors “picked” lanes from different gels or blots. The authors should show a single blot with all conditions or at least all conditions from one genotype. The authors should also include molecular weight indicators on the gels. This is because often the P-p70S6K antibodies also recognize P-p85 S6K and it is important to be sure that the authors are measuring P-p70 band.</p>
</sec>
<sec id="s7" sec-type="synthesis-author-response">
<title>Author Response</title>
<p>Dear Quentin,</p>
<p>Thank you very much for your careful consideration of our study and for passing along feedback from the reviewers. In response to these comments we have made a number of changes to the manuscript and included additional data that we believe greatly improve the manuscript. All amendments to the manuscript are highlighted, and Figure 1 has been changed to include our new data. We have also created Extended Data Figure 2-1 to show the original blots used for Figure 2, as requested by the reviewers, and full statistical table has been provided. We have also added RRIDs and figure legend contributions. A point-by-point response is below. </p>
<p>We feel these changes have significantly benefitted the manuscript and hope that this improved version will be accepted for publication in eNeuro. We look forward to hearing from you soon.</p>
<p>Sincerely,</p>
<p>Emily K. Osterweil, Ph.D.</p>
<p>Centre for Discovery Brain Sciences, Patrick Wild Centre</p>
<p>University of Edinburgh, Hugh Robson Building</p>
<p>George Square, Edinburgh, EH8 9XD</p>
<p>Email: Emily.osterweil@ed.ac.uk</p>
<p>1. Regarding the main text, this is well written but the results section of the manuscript at times serves as an extended section of the introduction, the methods and the discussion sections (first half of page 9 would better fit in the introduction, where mTORC1 pathway is not mentioned; page 12, lines 1-11 would better fit in the methods section; page 11 and other parts of the results section would better fit in the discussion section). The results section should concisely describe the experimental data, and the rest of information should be redistributed. </p>
<p>We thank the reviewer for pointing this out. The manuscript has now been streamlined to make the Results more succinct and move background information to the Introduction. All changes are highlighted.</p>
<p>2.Regarding the experimental data, Figure 1C does not show the phenotype between WT and Fmr1 KO mice, revealing some inconsistencies with the results previously published and those results shown in Figure 1 (B and D). Similarly, in the present experiments the enhanced ERK phosphorylation in basal conditions (Fmr1KO vs WT, in zero concentration of the drugs), previously published by other authors describing the effect of lovastatin, is not observed (Figure 2, B and C), raising questions about the performance of the assay. </p>
<p>The reviewer is correct that a genotype difference in protein synthesis did not pull out of the dataset shown in Figure 1C. We feel this is due to insufficient sample size in that dataset and have performed additional experiments for vehicle vs 5 µM simvastatin and the genotype effect has become significant by ANOVA (see revised Figure 1C). A post-hoc paired t-test shows a significant difference between vehicle WT and KO (provided in the statistical table).</p>
<p>Regarding the difference in p-ERK1/2 in WT versus Fmr1-/y hippocampus, previous work has shown that this is in fact not different between genotypes (Osterweil et al., 2010; Osterweil et al., 2013). These studies show that the greater impact of ERK1/2 and mGlu5 inhibitors on protein synthesis in the Fmr1-/y model is not due to a hyperactivation of the singaling cascade, but is rather due to a hypersensitive response to the same amount of ERK1/2 activation. The results shown in Figure 2 are consistent with these previous studies.</p>
<p>3. Other minor drawback is the representative image chosen in Figure 1D. In the representative image for 35S detection, the WT 0 condition and WT 0.5 condition do not seem to reflect the averaged differences observed in the bars plot when comparing the darkest gray column and the lightest gray column. </p>
<p>We have now revised this figure to include images that emphasize the difference between vehicle and 0.5 µM simvastatin.</p>
<p>4. Please detail in the methods how the protein synthesis and _pERK values are normalized. Are all values normalized to WT veh or to vehicle within the same genotype? </p>
<p>Protein synthesis is calculated by liquid scintillation counting from TCA-precipitated samples, with CPM divided by total protein quantified by Protein Concentration assay. The phosphorimages shown in Figure 1 are for representative purposes only. </p>
<p>To compare phopho- to total for each target in the same lane, membranes developed for phospho (i.e., p-ERK1/2) were stripped and re-probed for total (i.e., ERK1/2). Phosphorylation of target proteins was calculated as a ratio of phospho- to total. To correct for blot-to-blot variance, each signal was normalized to the average signal of all lanes on the same blot. Our gels are run such that each contains yoked pairs of WT-KO and veh-drug, ensuring that the average is not skewed by any one condition. Values are shown as a percentage of average WT vehicle for graphical purposes. </p>
<p>These details have been added to the Materials and Methods section.</p>
<p>5. From the representative western blots in Fig. 2, the appropriate inclusion of a line between the WT and the KO indicates that each lane is cut or separated from adjacent lanes, suggesting that the authors “picked” lanes from different gels or blots. The authors should show a single blot with all conditions or at least all conditions from one genotype. The authors should also include molecular weight indicators on the gels. This is because often the P-p70S6K antibodies also recognize P-p85 S6K and it is important to be sure that the authors are measuring P-p70 band.</p>
<p>We apologize for the confusion. Our samples were taken from the same blots, however we load these samples blind to genotype and treatment and they were therefore rearranged for the figure. The original membranes are now presented in Figure 2-1 showing the original sample loading. </p>
<p>We are aware of the issue with the p-p70S6K antibody and we therefore adopt a membrane cutting strategy to avoid the p85S6K antigen. Membranes are cut at 75KDa and 50KDa and the portion of membrane above 75KDa is removed to eliminate the background p85S6K band. This strategy is now explained in the Materials and Methods and we have included images of the membranes in Figure 2-1.</p>
</sec>
</back>
</article>
</pmc-articleset>